var title_f24_38_25184="HSV recrudescence";
var content_f24_38_25184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpex simplex virus (HSV) recrudescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HSV recrudescence in a patient with chronic graft versus host disease following allogeneic hematopoietic cell transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nathaniel Treister, DMD, DMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25184=[""].join("\n");
var outline_f24_38_25184=null;
var title_f24_38_25185="Irving tubal ligation E";
var content_f24_38_25185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Irving tubal ligation E",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25185=[""].join("\n");
var outline_f24_38_25185=null;
var title_f24_38_25186="Small bowel angiodysplasia";
var content_f24_38_25186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel angiodysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiodysplasia detected in the small bowel during double balloon enteroscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hiroto Kita, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25186=[""].join("\n");
var outline_f24_38_25186=null;
var title_f24_38_25187="Aortic coarctation PI";
var content_f24_38_25187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Aortic coarctation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aorta is the main artery that delivers blood from the heart to the body. Aortic coarctation is a heart defect that causes the aorta to narrow (see arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25187=[""].join("\n");
var outline_f24_38_25187=null;
var title_f24_38_25188="Penicillin G benzathine and penicillin G procaine: Drug information";
var content_f24_38_25188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G benzathine and penicillin G procaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/18/22819?source=see_link\">",
"    see \"Penicillin G benzathine and penicillin G procaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; C-R;",
"     </li>",
"     <li>",
"      Bicillin&reg; C-R 900/300",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Streptococcal infections: I.M.: 2.4 million units in a single dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Streptococcal infections:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;14 kg: 600,000 units in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-27 kg: 900,000 units to 1.2 million units in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;27 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Rheumatic fever, primary prevention (Bicillin&reg; C-R 900/300):",
"     </b>",
"     Children 6 months to 12 years: 1.2 million units as a single dose (Bass, 1976; Gerber, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     The efficacy of this regimen for heavier patients is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [prefilled syringe]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicillin&reg; C-R:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     600,000 units: Penicillin G benzathine 300,000 units and penicillin G procaine 300,000 units per 1 mL (1 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1,200,000 units: Penicillin G benzathine 600,000 units and penicillin G procaine 600,000 units per 2 mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2,400,000 units: Penicillin G benzathine 1,200,000 units and penicillin G procaine 1,200,000 units per 4 mL (4 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicillin&reg; C-R 900/300: 1,200,000 units: Penicillin G benzathine 900,000 units and penicillin G procaine 300,000 units per 2 mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by deep I.M. injection in the upper outer quadrant of the buttock; in infants and children, I.M. injections should be made into the midlateral muscle of the thigh. Do not inject near an artery or a nerve; permanent neurological damage or gangrene may result.",
"     <b>",
"      Do not administer I.V., intravascularly, or intra-arterially.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be used in specific situations in the treatment of streptococcal infections; primary prevention of rheumatic fever",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Penicillin may be confused with penicillamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bicillin&reg; may be confused with Wycillin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin G benzathine may only be administered by deep intramuscular injection; intravenous administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bicillin&reg; C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin&reg; L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin&reg; L-A may result in inadequate treatment response.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin(s), procaine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Not for intravenous use; cardiopulmonary arrest and death have occurred from inadvertent I.V. administration.",
"     </b>",
"     Administer by deep I.M. injection only. Injection into or near an artery or nerve could result in severe neurovascular damage or permanent neurological damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5715759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5715761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4380079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Bicillin C-R 900/300 Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900000-300000 units/2 mL (2 mL): $60.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Bicillin C-R Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200000 units/2 mL (2 mL): $58.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9951551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: I.M.: Released slowly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Highest levels in the kidney; lesser amounts in liver, skin, intestines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: I.M.: Within 3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bass JW, Crast FW, Knowles CR, et al, &ldquo;Streptococcal Pharyngitis in Children: A Comparison of Four Treatment Schedules With Intramuscular Penicillin G Benzathine,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1976, 235(11):1112-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25188/abstract-text/765515/pubmed\" id=\"765515\" target=\"_blank\">",
"        765515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25188/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, &ldquo;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25188/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9870 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25188=[""].join("\n");
var outline_f24_38_25188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709200\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207718\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207728\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207721\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207725\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207722\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207710\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207695\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207712\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207711\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207735\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207726\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207714\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207699\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299840\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207704\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207707\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5715759\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5715761\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4380079\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207708\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207698\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9951551\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/18/22819?source=related_link\">",
"      Penicillin G benzathine and penicillin G procaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_38_25189="Polyethylene glycol electrolyte solution: Pediatric drug information";
var content_f24_38_25189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol electrolyte solution: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"    see \"Polyethylene glycol electrolyte solution: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34933?source=see_link\">",
"    see \"Polyethylene glycol electrolyte solution: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&reg;;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-C;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-G;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-N;",
"     </li>",
"     <li>",
"      GoLYTELY&reg;;",
"     </li>",
"     <li>",
"      MoviPrep&reg;;",
"     </li>",
"     <li>",
"      NuLYTELY&reg;;",
"     </li>",
"     <li>",
"      TriLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&trade;;",
"     </li>",
"     <li>",
"      Klean-Prep&reg;;",
"     </li>",
"     <li>",
"      PegLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Bowel Evacuant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Osmotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"      see \"Polyethylene glycol electrolyte solution: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;6 months, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bowel cleansing",
"     </b>",
"     (to prevent excessive fluid and electrolyte changes, use only products containing supplemental electrolytes for bowel cleansing): Patient should fast at least 2 hours (preferably 3-4 hours) prior to ingestion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, nasogastric: GaviLyte&trade;-N, NuLYTELY&reg;, and TriLyte&trade;: 25 mL/kg/hour until rectal effluent is clear (usually in ~4 hours). One study used 40 mL/hour intermittently by mouth or continuously by nasogastric drip in patients &ge;18 months (Sandheimer, 1991). Although not FDA approved for pediatric patients, other preparations have been used in pediatric studies: Colyte&reg;, GoLYTELY&reg; (Sondheimer, 1991; Tuggle, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Toxic ingestion",
"     </b>",
"     (AACT, 2004): Nasogastric tube:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ages &ge;9 months to 6 years: 500 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ages 6-12 years: 1000 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 1500-2000 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May take several hours for the rectal effluent to become clear. Duration may be extended if evidence of continued presence of toxins in GI tract (eg, radiographic evidence or ongoing elimination of toxins)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Bowel cleansing:",
"     </b>",
"     Patient should fast at least 2 hours (preferably 3-4 hours) prior to ingestion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Drink 240 mL (8 oz) every 10 minutes until 4 liters are consumed or the rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasogastric: 20-30 mL/minute (1.2-1.8 L/hour) until 4 liters are administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MoviPrep&reg;: Split-dose regimen: The evening prior to colonoscopy: 1000 mL over 1 hour (one 8 oz glass every 15 minutes) followed by 500 mL (16 oz) clear fluid; repeat the morning of the study and complete at least 1 hour prior to the start of the study",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MoviPrep&reg; Full-dose regimen: Beginning at 6 pm the night before the study and completed before bed: 1000 mL over 1 hour (one 8 oz glass every 15 minutes) followed 1.5 hours later with a second 1000 mL over 1 hour; administer an additional 1000 mL (approximately 32 oz) clear fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling (not studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling (not studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for solution, oral: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL); PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL); PEG 3350 240 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colyte&reg;: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g (3785 mL) [supplied with cherry, lemon lime, and orange flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colyte&reg;: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-C: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-G: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-N: PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GoLYTELY&reg;: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g per packet (1s) [regular flavor; makes 1 gallon of solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GoLYTELY&reg;: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [regular and pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MoviPrep&reg;: Pouch A: PEG 3350 100g, sodium sulfate 7.5 g, sodium chloride 2.69 g, potassium chloride 1.02 g; Pouch B: Ascorbic acid 4.7 g, sodium ascorbate 5.9 g (1000 mL) [contains phenylalanine 131 mg/treatment; lemon flavor; packaged with 2 of Pouch A and 2 of Pouch B in carton and a disposable reconstitution container]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NuLYTELY&reg;: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, lemon-lime, orange, and pineapple flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriLyte&reg;: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12808915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     MoviPrep&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: No solid foods for 2-4 hours prior to initiation of therapy; rapid drinking is preferred to drinking small amounts continuously; chilled solution often more palatable, but not recommended for infants; refrigerate reconstituted solution when not in use; do not add ingredients as flavorings before use; discard any unused portion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colyte&reg;, GaviLyte&trade;-C, GaviLyte&trade;-G, GaviLyte&trade;-N, GoLYTELY&reg;, NuLYTELY&reg;, and TriLyte&trade;: If using a flavor packet, add the flavor packet contents to the powder and shake well prior to adding water. Add tap water to \"fill-line\" for reconstitution and shake well until all ingredients have dissolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MoviPrep&reg;: Mix the contents of one pouch A and one pouch B to container. Add 1000 mL of lukewarm water; mix the solution until dissolved. Repeat mixing procedure if second liter is needed.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4298123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CoLyte&reg;, GaviLyte&trade;-C: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refrigerate reconstituted solution. Use within 48 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GaviLyte&trade;-G, GoLYTELY&reg;: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refrigerate reconstituted solution. Use within 48 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GaviLyte&trade;-N: Store at 25&deg;C (77&deg;F). Refrigerate reconstituted solution. Use within 48 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MoviPrep&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refrigerate reconstituted solution. Use within 24 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NuLYTELY&reg;, TriLyte&trade;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refrigerate reconstituted solution. Use within 48 hours of preparation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel cleansing prior to GI procedure (GaviLyte&trade;-N, NuLYTELY&reg;, Trilyte&trade;: FDA approved in ages &ge;6 months and adults; MoviPrep&reg;:  FDA approved in ages &ge;18 and adults; Colyte&reg;, GaviLyte&trade;-C, GaviLyte&trade;-G: FDA approved in adults); has also been used for whole bowel irrigation after toxic ingestions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GoLYTELY&reg; may be confused with NuLYTELY&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TriLyte&reg; may be confused with TriLipix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal distension, abdominal fullness, abdominal pain, anal irritation, bloating, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal cramps, abdominal fullness, allergic reactions, anaphylaxis, aspiration, asystole, bloating, chest tightness, dehydration, dermatitis, dyspnea (acute), esophageal perforation, facial edema, fever, flatulence, hypersensitivity reactions, hypokalemia (children), Mallory-Weiss tear, pulmonary edema, rash, rhinorrhea, seizure, shock, throat tightness, upper GI bleeding, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polyethylene glycol or any component, GI obstruction, illeus, gastric retention, bowel perforation, toxic colitis, megacolon",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May interfere with barium coating of intestinal wall using the double contrast technique. Use with caution in patients with ulcerative colitis, cardiac arrhythmias, or renal impairment. Use with caution and observe closely in patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration. Use in patients &lt;2 years of age may result in hypoglycemia, dehydration, and hypokalemia. Use MoviPrep&reg; with caution in patients with G6PD deficiency; contains ascorbic acid. MoviPrep&reg; also contains phenylalanine which must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizures associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia) have been reported; use with caution in patients with underlying hyponatremia or with concomitant administration of medications that alter electrolyte balance. Do not add additional ingredients as flavoring before use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted in animals or in humans.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes, BUN, serum glucose, urine osmolality; children &lt;2 years of age should be monitored for hypoglycemia, dehydration, hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces catharsis by strong electrolyte and osmotic effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Bowel cleansing: Within 1-2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34933?source=see_link\">",
"      see \"Polyethylene glycol electrolyte solution: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chilled solution is often more palatable but is not recommended for infants. For  bowel cleansing prior to GI exam, take every 10 minutes until recommended amount is consumed or the stool is watery and  clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. The first bowel movement should occur ~1 hour after the start of administration. May cause abdominal bloating and distention before bowel starts to move; if severe discomfort or distention occurs, stop drinking temporarily or drink each portion at longer intervals until these symptoms disappear. Continue drinking until the watery stool is clear and free of solid matter.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F16319576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concentrations for reconstituted solutions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     When prepared as recommended by the manufacturer, the solutions will contain:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CoLyte&reg;, GaviLyte&trade;-C: When dissolved in sufficient water to make 4000 mL, the final solution contains PEG-3350 60 g/L, sodium 125 mEq/L, sulfate 80 mEql/L, chloride 35 mEql/L, bicarbonate 20 mEq/L, and potassium 10 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GaviLyte&trade;-G, GoLYTELY&reg;: When dissolved in sufficient water to make 4000 mL, the final solution contains PEG-3350 59 g/L, sodium 125 mEq/L, sulfate 40 mEq/L, chloride 35 mEq/L, bicarbonate 20 mEq/L, and potassium 10 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GaviLyte&trade;-N, NuLYTELY&reg;, TriLyte&reg;: When dissolved in sufficient water to make 4000 mL, the final solution contains PEG-3350 105 g/L, sodium 65 mEq/L, chloride 53 mEq/L, bicarbonate 17 mEq/L, and potassium 5 mEq/L",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists, \"Position Paper: Whole Bowel Irrigation,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(6):843-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25189/abstract-text/15533024/pubmed\" id=\"15533024\" target=\"_blank\">",
"        15533024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sondheimer JM, Sokol RJ, Taylor SF, et al, &ldquo;Safety, Efficacy and Tolerance of Intestinal Lavage in Pediatric Patients Undergoing Diagnostic Colonoscopy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(1):148-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25189/abstract-text/2066847/pubmed\" id=\"2066847\" target=\"_blank\">",
"        2066847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuggle DW, Hoelzer DJ, Tunell WP, et al, &ldquo;The Safety and Cost-Effectiveness of Polyethylene Glycol Electrolyte Solution Bowel: Preparation in Infants and Children,&rdquo;",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1987, 22(6):513-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/38/25189/abstract-text/311235/pubmed\" id=\"311235\" target=\"_blank\">",
"        311235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12715 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25189=[""].join("\n");
var outline_f24_38_25189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061227\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061220\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211104\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808915\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061230\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4298123\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061229\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211145\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211144\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061233\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061219\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061218\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299900\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222413\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211100\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211113\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061226\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061217\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061232\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061224\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16319576\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34933?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_38_25190="Diagnosis of urinary tract obstruction and hydronephrosis";
var content_f24_38_25190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of urinary tract obstruction and hydronephrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25190/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/38/25190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract obstruction (UTO) is a relatively common problem. The obstruction to urinary flow may be acute or chronic, partial or complete, unilateral or bilateral, and may occur at any site in the urinary tract. The major causes of UTO vary with the age of the patient. Anatomic abnormalities (including urethral valves or stricture, and stenosis at the ureterovesical or ureteropelvic junction) account for the majority of cases in children. In comparison, calculi are most common in young adults, while prostatic hypertrophy or carcinoma, retroperitoneal or pelvic neoplasms, and calculi are the primary causes in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link&amp;anchor=H9#H9\">",
"     \"Malignancies of the renal pelvis and ureter\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the diagnosis of urinary tract obstruction and hydronephrosis in adults. Hydronephrosis in infants and children is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link\">",
"     \"Congenital ureteropelvic junction obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=see_link\">",
"     \"Primary megaureter in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of UTO vary with the site, degree, and rapidity of onset of the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is frequently present, due to distention of the bladder, collecting system, or renal capsule. Pain is typically minimal or absent with partial or slowly developing obstruction (as with congenital ureteropelvic junction [UPJ] obstruction or a pelvic tumor). It is not uncommon, for example, to see an adult who is noted to have hydronephrosis due to previously unsuspected UPJ obstruction.",
"   </p>",
"   <p>",
"    In comparison, relatively severe pain (renal or ureteral colic) may be seen with acute complete obstruction (as with a ureteral calculus) or when acute dilatation occurs after a fluid load that increases the urine output to a level",
"    <strong>",
"     greater than the flow rate",
"    </strong>",
"    through the area of obstruction. An example of the latter problem occurs after beer drinking in a college student with previously asymptomatic and unsuspected UPJ obstruction.",
"   </p>",
"   <p>",
"    The site of obstruction determines the location of pain. Upper ureteral or renal pelvic lesions lead to flank pain or tenderness, whereas lower ureteral obstruction may cause flank pain or pain that radiates to the ipsilateral testicle or labia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complete or severe partial bilateral obstruction also may develop acute or chronic renal failure. In the latter setting, the patient is often asymptomatic and the urinalysis may be relatively normal or reveal only a few white cells or red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, UTO should be considered in all patients with otherwise unexplained renal insufficiency. The history may be helpful in some cases, possible revealing symptoms of prostatic enlargement or prior malignancy or renal calculi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary findings are generally nondiagnostic with one possible exception: anuria. Although the urine volume can be reduced in any form of renal disease, anuria is most often seen in two conditions: complete bilateral UTO and shock. Other less common causes of anuria are the hemolytic-uremic syndrome, renal cortical necrosis, bilateral renal arterial obstruction, and crescentic or rapidly progressive glomerulonephritis, particularly anti-GBM antibody disease.",
"   </p>",
"   <p>",
"    It is important to remember, however, that a normal or even elevated urine output does not exclude partial obstruction. The latter can cause tubular injury that over time impairs both concentrating ability and sodium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These defects can maintain the urine output and even cause symptoms of nocturia or polyuria, despite the presence of a reduced glomerular filtration rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the findings in bilateral disease, the plasma creatinine concentration is usually normal or only slightly elevated in patients with unilateral obstruction due to presence of the normal contralateral kidney. In rare cases, however, unilateral obstruction leads to anuria and acute renal failure; vascular or ureteral spasm, mediated by autonomic activation, is thought to be responsible for the loss of function in the nonobstructed kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperkalemic renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal renal tubular acidosis with hyperkalemia is described with urinary tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/2\">",
"     2",
"    </a>",
"    ]. Distal tubular injury in this setting may diminish sodium reabsorption by reducing the activity of the cellular Na-K-ATPase. In turn, impairing sodium reabsorption will tend to induce both metabolic acidosis and hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is occasionally induced by UTO. The mechanism responsible for the elevation in blood pressure varies with the duration and type of obstruction. What remains unclear, however, is the factors described below result in hypertension in only a minority of obstructed patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute, unilateral obstruction can cause hypertension via activation of the renin-angiotensin system; renal vein renin studies lateralize the increase in renin secretion to the obstructed kidney, a finding similar to that in unilateral renal artery stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renin secretion is usually normal in patients with bilateral UTO or obstruction of a solitary functioning kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/7\">",
"       7",
"      </a>",
"      ]. In this condition, renal failure leading to volume expansion is typically present; the elevation is blood pressure is probably volume-mediated and resolves with the diuresis following correction of the obstruction.",
"     </li>",
"     <li>",
"      The plasma renin activity is also typically normal in chronic unilateral obstruction and the presence of the contralateral normal kidney prevents both renal failure and fluid retention [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/7\">",
"       7",
"      </a>",
"      ]. Furthermore, relief of the obstruction may not correct the hypertension. These observations suggest that there may be some permanent damage to the kidney and that the elevation in blood pressure is unrelated to the renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis of UTO is important, since most cases can be corrected and a delay in therapy can lead to irreversible renal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bladder catheterization should be performed initially if there is reason to suspect that bladder neck obstruction leading to acute or chronic urinary retention may be present. Possible clues to this diagnosis include suprapubic pain, a palpable bladder, or an older man with unexplained renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiologic tests are generally used to exclude obstruction at the level of the ureters or above. These procedures are dependent upon their ability to detect dilatation of the collecting system (hydronephrosis). It is important to remember, therefore, that there are three settings in which obstruction can occur without dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within the first one to three days, when the collecting system is relatively uncompliant and less likely to dilate. In this setting, unilateral obstruction can usually be diagnosed by duplex Doppler ultrasonography, which detects an increased resistive index (a reflection of increased renal vascular resistance) in the affected compared to the contralateral kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/10\">",
"       10",
"      </a>",
"      ]. This test is of no value with bilateral involvement, since it cannot distinguish obstruction from intrinsic renal disease.",
"     </li>",
"     <li>",
"      When the collecting systems are encased by retroperitoneal tumor or fibrosis. In this setting, hydronephrosis may be present in the absence of ureteral dilatation. Retroperitoneal fibrosis can occur in a number of settings including retroperitoneal fibrosis (most commonly idiopathic or associated with beta blocker or methysergide use, malignancy, or a connective tissue disorder) and with the fibrotic reaction that surrounds a renal transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/11\">",
"       11",
"      </a>",
"      ]. Thus, the diagnosis of renal insufficiency due to asymptomatic obstruction in a transplanted kidney may be made on renal biopsy which shows diffuse tubular dilatation, rather than the signs of rejection or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      nephrotoxicity.",
"     </li>",
"     <li>",
"      When the obstruction is mild, a setting in which there is usually no impairment in renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal ultrasonography is the test of choice to exclude UTO, avoiding the potential allergic and toxic complications of radiocontrast media (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77938 \" href=\"UTD.htm?10/0/10246\">",
"     image 1",
"    </a>",
"    ). It can, in the majority of affected patients, diagnose hydronephrosis and establish its cause; it can also detect other causes of renal disease such as polycystic kidney disease. CT scanning should be performed if the ultrasound results are equivocal or the kidneys cannot be well visualized, or if the cause of the obstruction cannot be identified.",
"   </p>",
"   <p>",
"    The combination of a plain film of the abdomen (including tomographic cuts to detect radiopaque calculi), ultrasonography, and, if necessary, CT scanning will be adequate for diagnostic purposes in over 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. It should be noted, however, that the false positive rate of ultrasonography may be as high as 25 percent if only minimal criteria (any visualization of the collecting systems) are used to diagnose obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intravenous pyelogram (IVP) has a number of advantages in relation to ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65559 graphicRef73212 \" href=\"UTD.htm?28/35/29234\">",
"     image 2A-B",
"    </a>",
"    ). The false positive rate is very low, it can identify the site of obstruction, and it can detect associated conditions such as papillary necrosis or caliceal blunting from previous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, an IVP is more cumbersome to perform and requires the administration of a radiocontrast agent. As a result, it can be used to screen for UTO in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With staghorn calculi or multiple renal or parapelvic cysts, since hydronephrosis is usually not distinguishable from cysts or stones by ultrasonography or CT scanning.",
"     </li>",
"     <li>",
"      When CT scanning cannot identify the level of obstruction.",
"     </li>",
"     <li>",
"      With suspected acute obstruction due to kidney stones (or less frequently, to other problems, such as a sloughed papilla or blood clot); dilatation of the collecting system may not be seen at this time, but the presence and location of the obstructing stone can be identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antegrade or retrograde pyelography is usually used to relieve, rather than diagnose, UTO. These tests, however, can also be performed for diagnosis when the history is highly suggestive (unexplained acute renal failure in a patient with known pelvic malignancy), even though hydronephrosis may be absent (due to possible ureteral encasement) on ultrasonography and CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion-weighted MR imaging may allow non-invasive detection of changes in renal perfusion and diffusion that occur during acute ureteral obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/13\">",
"     13",
"    </a>",
"    ]. The advantage of this method is that it does not require the use of contrast agents. However the clinical utility of this method has not been adequately tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYDRONEPHROSIS WITHOUT APPARENT OBSTRUCTION OR WITH ASYMPTOMATIC OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, one of the above radiologic tests demonstrates hydronephrosis without evident obstruction. This is a normal finding in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .) Megaureter due to previous marked vesicoureteral reflux or a dilated but nonobstructed extrarenal pelvis is the most common example of this problem. These patients are often being evaluated for back or flank pain and two questions need to be answered: (1) Is obstruction present? and (2) Is the obstruction responsible for the pain?",
"   </p>",
"   <p>",
"    In this setting, three different tests have been used: the diuretic renogram or, less often, IVP and perfusion pressure flow studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/8,14-17\">",
"     8,14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diuretic renogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic renography involves the administration of a loop diuretic (such as 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) prior to a radionuclide renal scan or during an IVP, while the latter involves percutaneous insertion of a catheter into the dilated renal pelvis, followed by fluid perfusion into the pelvis at a rate of 10",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The marked increase in urine flow should, if obstruction is present, slow the rate of washout of the radioisotope during a renal scan, further increase the size of the collecting system on IVP, or elevate the renal pelvic pressure to above 22 mmHg during a perfusion study. Furthermore, any of these procedures may precipitate pain similar to the patient's initial complaint.",
"   </p>",
"   <p>",
"    The noninvasive diuretic renogram is generally preferred. However, optimal interpretation of either of these tests is uncertain, because both false positive and false negative tests may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Nevertheless, the following general recommendations have been made [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical correction should be considered in a patient with pain and a positive diuretic renogram.",
"     </li>",
"     <li>",
"      No therapy is necessary in an asymptomatic patient with a positive diuretic renogram but normal renal function. These patients often present as adults and have therefore had the partial obstruction for many years without apparent damage to the kidney. Hydronephrosis may be first noted after a radiologic study is done for some other reason or, as noted above, obstruction may be suspected when pain is induced after a period of high fluid intake leads to a diuresis that exceeds the rate at which urine can flow through the obstructed area. Similarly, the decreased washout observed on the renogram occurs only at a urine flow rate much higher than the patient is likely to achieve on his or her own. Periodic monitoring of renal function and renal parenchymal size (by ultrasonography) is indicated in these patients to exclude progressive renal injury.",
"     </li>",
"     <li>",
"      No therapy is indicated in an asymptomatic patient with a negative renogram. Long-term follow-up has demonstrated stable renal function in most of these patients.",
"     </li>",
"     <li>",
"      A perfusion pressure flow study should be performed in a symptomatic patient with a negative or equivocal diuretic renogram. Some nonrenal cause for the pain is probably present if the perfusion study is negative. On the other hand, a positive study is suggestive of obstruction and the need for surgical correction.",
"     </li>",
"     <li>",
"      A perfusion pressure flow study may also be performed in patients with hydronephrosis and poor renal function. The diuretic renogram may be falsely negative in this setting, because the diuretic may not sufficiently raise the urine flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, approximately 50 percent of patients with a positive diuretic renogram will eventually require surgery, either for pain or progressive parenchymal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25190/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=see_link\">",
"       \"Patient information: Hydronephrosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1215097326\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract obstruction (UTO) is a relatively common problem. The obstruction to urinary flow may be acute or chronic, partial or complete, unilateral or bilateral, and may occur at any site in the urinary tract. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major causes of UTO vary with the age of the patient. Anatomic abnormalities are most common in children; calculi in young adults; and prostatic hypertrophy or carcinoma, retroperitoneal or pelvic neoplasms, and calculi are the primary causes in older patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain may be present with acute complete obstruction but is typically minimal or absent with partial or slowly developing obstruction. The site of obstruction determines the location of pain. Upper ureteral or renal pelvic lesions lead to flank pain or tenderness, whereas lower ureteral obstruction may cause flank pain or pain that radiates to the ipsilateral testicle or labia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with complete or severe partial bilateral obstruction may develop acute or chronic renal failure. UTO should be considered in all patients with otherwise unexplained renal insufficiency. The urinary findings are nondiagnostic but the presence of anuria is very suggestive of UTO. However a normal or even elevated urine output does not exclude partial obstruction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal renal tubular acidosis with hyperkalemia may occur with UTO. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hyperkalemic renal tubular acidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension is occasionally induced by UTO. The mechanism responsible for the elevation in blood pressure varies with the duration and type of obstruction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis of UTO is important, since most cases can be corrected and a delay in therapy can lead to irreversible renal injury: (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bladder catheterization should be performed if there is reason to suspect that bladder neck obstruction leading to acute or chronic urinary retention may be present. Possible clues to this diagnosis include suprapubic pain, a palpable bladder, or an older man with unexplained renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal ultrasonography is the radiographic test of choice to exclude UTO. CT scanning should be performed if the ultrasound results are equivocal or the kidneys cannot be well visualized, or if the cause of the obstruction cannot be identified.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Black, RM. Manual of Clinical Problems in Nephrology, Little, Brown, Boston, 1988, pp. 337-343.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/2\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/3\">",
"      Klahr S. Pathophysiology of obstructive nephropathy. Kidney Int 1983; 23:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/4\">",
"      Hanley MJ, Davidson K. Isolated nephron segments from rabbit models of obstructive nephropathy. J Clin Invest 1982; 69:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/5\">",
"      Maletz R, Berman D, Peelle K, Bernard D. Reflex anuria and uremia from unilateral ureteral obstruction. Am J Kidney Dis 1993; 22:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/6\">",
"      Weidmann P, Beretta-Piccoli C, Hirsch D, et al. Curable hypertension with unilateral hydronephrosis. Studies on the role of circulating renin. Ann Intern Med 1977; 87:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/7\">",
"      Vaughan ED Jr, B&uuml;hler FR, Laragh JH. Normal renin secretion in hypertensive patients with primarily unilateral chronic hydronephrosis. J Urol 1974; 112:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/8\">",
"      Webb JA. Ultrasonography in the diagnosis of renal obstruction. BMJ 1990; 301:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/9\">",
"      Rascoff JH, Golden RA, Spinowitz BS, Charytan C. Nondilated obstructive nephropathy. Arch Intern Med 1983; 143:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/10\">",
"      Platt JF, Rubin JM, Ellis JH. Acute renal obstruction: evaluation with intrarenal duplex Doppler and conventional US. Radiology 1993; 186:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/11\">",
"      Demko TM, Diamond JR, Groff J. Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Nephrol 1997; 8:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/12\">",
"      Webb JA, Reznek RH, White FE, et al. Can ultrasound and computed tomography replace high-dose urography in patients with impaired renal function? Q J Med 1984; 53:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/13\">",
"      Thoeny HC, Binser T, Roth B, et al. Noninvasive assessment of acute ureteral obstruction with diffusion-weighted MR imaging: a prospective study. Radiology 2009; 252:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/14\">",
"      O'Reilly PH. Diuresis renography 8 years later: an update. J Urol 1986; 136:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/15\">",
"      Hydronephrosis, renal obstruction, and renography. Lancet 1987; 1:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/16\">",
"      Whitaker RH, Buxton-Thomas MS. A comparison of pressure flow studies and renography in equivocal upper urinary tract obstruction. J Urol 1984; 131:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25190/abstract/17\">",
"      Lupton EW, Testa HJ. The obstructive diuresis renogram: an appraisal of the significance. J Urol 1992; 147:981.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7174 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E9FFDB1ABC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25190=[""].join("\n");
var outline_f24_38_25190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1215097326\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Urine output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperkalemic renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYDRONEPHROSIS WITHOUT APPARENT OBSTRUCTION OR WITH ASYMPTOMATIC OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diuretic renogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1215097326\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7174|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/0/10246\" title=\"diagnostic image 1\">",
"      Ultrasound showing hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/57/17311\" title=\"diagnostic image 2A\">",
"      Intravenous pyelogram showing massive bilateral hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/4/12367\" title=\"diagnostic image 2B\">",
"      IVP in obstruction II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=related_link\">",
"      Congenital ureteropelvic junction obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=related_link\">",
"      Patient information: Hydronephrosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=related_link\">",
"      Primary megaureter in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=related_link\">",
"      Recovery of renal function after relief of urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_38_25191="Breastfeeding positions PI";
var content_f24_38_25191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Different holds for breastfeeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 663px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These drawings show different ways you can hold your baby for breastfeeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25191=[""].join("\n");
var outline_f24_38_25191=null;
var title_f24_38_25192="Large cell lung CA";
var content_f24_38_25192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell undifferentiated carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing large cell undifferentiated carcinoma of the lung. The tumor cells have vesicular nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm. The cells are arranged in sheets without distinct architectural features.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25192=[""].join("\n");
var outline_f24_38_25192=null;
var title_f24_38_25193="Management of radiation exposure in children following a nuclear disaster";
var content_f24_38_25193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of radiation exposure in children following a nuclear disaster",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Joseph Y Allen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25193/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/38/25193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation exposure in children is a rare occurrence. However, the potential for radiation exposure is significant.",
"   </p>",
"   <p>",
"    Physicians who treat patients who are exposed to radiation must understand the biologic effects of the various types of radiation in order to determine which patients are at risk for radiation injury, to manage patients with radiation exposure, and to minimize the risk of contamination of hospital equipment and personnel.",
"   </p>",
"   <p>",
"    The management of the various types of radiation injury in children will be reviewed here. Clinical features of radiation injury in children and adults, treatment of radiation injury adults, and the emergency care of thermal burns in children and adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link\">",
"       \"Clinical features of radiation exposure in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"       \"Biology and clinical features of radiation injury in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=see_link\">",
"       \"Treatment of radiation injury in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of radiation exposure, for an individual or a community, requires knowledge of the principles of radiation safety and advance preparation and planning at both the community and healthcare facility level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiation safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection from radiation exposure is accomplished through [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimizing the time of exposure",
"     </li>",
"     <li>",
"      Maximizing the distance from the source (if possible)",
"     </li>",
"     <li>",
"      Using a shield as appropriate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maximizing the distance from the exposure source is the most practical and effective method [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/1\">",
"     1",
"    </a>",
"    ]. This is because the radiation dose decreases by the square of the distance from the source (eg, doubling the distance decreases the exposure by a factor of four), a relationship known as the inverse square law. The protective effect of shielding in radiation accidents is limited. This is because radiation accidents usually involve high-energy gamma radiation and the amount of shielding that would be necessary for adequate protection is not practical [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/1\">",
"     1",
"    </a>",
"    ]. Respiratory protection for medical providers with an N-95 mask is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Communities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, maximizing the distance from the exposure source is the most effective protective strategy. Thus, if at all possible after radiation release from a nuclear disaster, evacuation of the area of exposure should be undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/2\">",
"     2",
"    </a>",
"    ]. Federal, state, and local agencies will determine whether the need for relocation is temporary or long-term depending upon the persistence of radiation, physical damage to roads and buildings, and other factors affecting population safety [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shielding, or sheltering, is a reasonable alternative if evacuation is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/2\">",
"     2",
"    </a>",
"    ]. A safe place should be sought within the home or other building. The shielding factor (the ratio of the dose of radiation received within a structure to that if the structure were not present) varies depending upon the type of structure, and the location within the structure. As an example, the shielding factor for gamma radiation after a radioactive cloud release in various locations is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wooden frame structure &ndash; 0.9",
"     </li>",
"     <li>",
"      Home basement &ndash; 0.6",
"     </li>",
"     <li>",
"      Home basement in a masonry home &ndash; 0.4",
"     </li>",
"     <li>",
"      Large office or industrial building &ndash; 0.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for evacuation or sheltering may arise while children are at school or day care. Families and school or child care facilities should make a plan for reunification in the event that a radiation accident occurs during these times. The duration of sheltering that is necessary depends upon the extent of environmental contamination from the nuclear disaster [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/2\">",
"     2",
"    </a>",
"    ]. Families should follow the instructions provided by the emergency broadcast system.",
"   </p>",
"   <p>",
"    In addition, in December 2001, the Nuclear Regulatory Commission (NRC) offered to provide two",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=see_link\">",
"     potassium iodide",
"    </a>",
"    tablets (the mainstay of preventive treatment after known or suspected exposure to radioactive iodine) to every person living within 10 miles of a nuclear power plant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/4\">",
"     4",
"    </a>",
"    ]. Rapid administration of this drug, in the event of exposure to radioactive iodine, requires that supplies are pre-deployed at homes, schools, and day care centers that are located within the 10-mile radius.",
"   </p>",
"   <p>",
"    Information on dosage and available preparations (including instructions on how to mix the tablets with food or drink to make them palatable for infants and small children) can be found at",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm\">",
"     file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link&amp;anchor=H16#H16\">",
"     \"Radiation-induced thyroid cancer\", section on 'Potassium iodide for thyroid protection in a nuclear accident'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Health care facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Joint Commission for the Accreditation of Healthcare Organizations (JCAHO) requires every hospital in the United States to have a written plan in place to deal with the victims of a nuclear disaster [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/5\">",
"     5",
"    </a>",
"    ]. To be able to handle such an emergency effectively, major referral hospitals and hospitals that function as the designated receiving center for victims of radiation accidents should rehearse the protocol until it is familiar to all staff members who may need to participate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ]. Rehearsal of and familiarity with the protocols help to expedite care, to prevent contamination, and to educate medical staff about the biologic risks of radiation and radiation safety. All emergency departments should have ready access to the supplies and equipment necessary in the management of radiation accidents (",
"    <a class=\"graphic graphic_table graphicRef71406 \" href=\"UTD.htm?41/28/42443\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment area",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, contaminated patients should enter the treatment facility through a separate entrance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/7\">",
"     7",
"    </a>",
"    ]. The entryway should be covered with paper or waterproof sheets that are taped to the ground or floor. If a separate entrance is not available, the contaminated patient can be placed on a clean stretcher outside the emergency department and wrapped in a cloth sheet before transport to the desired area of the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features of radiation exposure in children\", section on 'Contamination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the areas traversed by contaminated patients should be taped off and labeled as radioactive. A buffer zone between the contaminated and uncontaminated areas helps to prevent the spread of radioactive material. Designated personnel should remain in this area to transfer material from \"clean\" to \"dirty\" by taking uncontaminated material from the clean side and directly handing it to personnel in the contaminated area without individual-to-individual contact. If at all possible, a radiation safety specialist should be on hand to monitor levels of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decontamination room should be separate from the rest of the treatment areas of the emergency department. Areas, such as autopsy rooms, casting areas, or isolated areas of the emergency department, can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/10\">",
"     10",
"    </a>",
"    ]. The ventilation system of the decontamination room should be separate from that of the remainder of the hospital. If a separate ventilation system is not in place, the ventilation to the room should be turned off to avoid the spread of radioactive particles. Nonessential equipment should be removed from the room. All handles, switches, and essential equipment should be covered with masking tape, paper tape, or other nonpermeable covering that is sealed with tape.",
"   </p>",
"   <p>",
"    The decontamination room must be equipped with instruments for monitoring radiation (eg, alpha counters and Geiger-Muller counters). Scrub suits, gowns, gloves, masks, hats, and foot covers should be readily available. After the protective gear is donned by personnel, all openings should be taped closed to create a complete and intact barrier. Plastic bags, waste containers, and lead containers must be available for storage and disposal of contaminated material (",
"    <a class=\"graphic graphic_table graphicRef71406 \" href=\"UTD.htm?41/28/42443\">",
"     table 1",
"    </a>",
"    ). The decontamination process is discussed in detail below (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Decontamination'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Real-time dosimeters must be worn by healthcare providers to monitor their total radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,8-13\">",
"     6,8-13",
"    </a>",
"    ]. Film badges are not recommended because they do not provide real time measurements. The National Council on Radiation Protection and Measurements recommends a maximum of 100 rem (1 Sv) of exposure for providers in lifesaving emergency situations and 25 rem (0.25 Sv) in less urgent situations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/9\">",
"     9",
"    </a>",
"    ]. Personnel should be rotated to minimize exposure. Pregnant personnel should be excluded from the treating team.",
"   </p>",
"   <p>",
"    Once decontamination is complete, all tape and protective coverings should be removed and disposed of in labeled bags, and the area should be rechecked. As they exit the decontamination room, decontamination personnel enter the buffer zone, where they remove their outer protection, turning the garments inside out. They label their dosimeter badges and turn them in to the radiation officer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,8,9,11,12\">",
"     6,8,9,11,12",
"    </a>",
"    ]. When decontamination is complete, the radiation safety inspector performs a final sweep of the entrance, the transferring area, the buffer zone, and the treatment area to ensure that no excessive radiation remains before the treatment team leaves the contamination area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once notified of a radiation accident, the receiving facility should try to obtain a detailed account of the accident in order to determine the nature of the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What radioactive substances were involved (",
"      <a class=\"graphic graphic_table graphicRef82388 \" href=\"UTD.htm?10/47/11005\">",
"       table 2",
"      </a>",
"      )?",
"     </li>",
"     <li>",
"      What type of exposure(s) occurred (eg, contamination, incorporation, acute partial body exposure, acute whole body exposure)?",
"     </li>",
"     <li>",
"      How many victims were involved?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A radiation safety officer at the receiving facility should be notified and made responsible for monitoring radiation levels, overseeing the storage and disposal of decontaminated materials, and ensuring that contamination is eliminated. A radiology technician with training in dosimetry can serve in this role if the facility does not have a designated radiation safety officer.",
"   </p>",
"   <p>",
"    The Radiation Emergency Assistance Center and Training Site",
"    <span class=\"nowrap\">",
"     (REAC/TS)",
"    </span>",
"    at Oak Ridge, Tennessee is a part of the Department of Energy and provides 24-hour medical consultation and assistance (",
"    <a class=\"external\" href=\"file://orise.orau.gov/reacts/\">",
"     file://orise.orau.gov/reacts/",
"    </a>",
"    ). The telephone number is 865-576-1005. Consultation with",
"    <span class=\"nowrap\">",
"     REAC/TS",
"    </span>",
"    is sometimes necessary before the FDA will release certain medications for management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/8\">",
"     8",
"    </a>",
"    ]. The treating facility is not required to notify",
"    <span class=\"nowrap\">",
"     REAC/TS.",
"    </span>",
"    However, the facility at which the exposure occurred is required to report all incidents of accidental exposure of nuclear compounds to the Department of Energy.",
"   </p>",
"   <p>",
"    The first priority in the management of children who are exposed to radiation is stabilization of life- and limb-threatening conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate therapy for radiation effects is rarely necessary except in individuals who received extremely high (and probably lethal) doses of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/14\">",
"     14",
"    </a>",
"    ]. The effects of radiation exposure that require treatment usually manifest after a latency period of days to weeks. After medical stabilization, decontamination is initiated to minimize continued irradiation in individuals who have been contaminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency departments that are eligible to receive victims of radiation accidents must be prepared to manage large numbers of victims. In mass casualty situations, the receiving hospital must triage patients according to its capabilities, with priority given to those who are likely to survive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. If resources are limited, it may be necessary to provide palliative care only (eg, pain control, antiemetics, antiepileptics) to victims who are known to have received a lethal dose of gamma radiation.",
"   </p>",
"   <p>",
"    Appropriate triage of victims requires accurate estimation of the received dose of radiation. Initial estimates of radiation dose are based upon the timing, severity, and duration of symptoms; these estimates are revised based upon laboratory studies that are performed as soon as is practical (see below).",
"   </p>",
"   <p>",
"    As a general rule, patients who demonstrate symptoms within two hours of exposure should be assumed to have received a high and possibly lethal dose of radiation. However, it is important to remember that some symptoms, such as nausea, vomiting, and diarrhea, may be caused by stress rather than the acute radiation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/14\">",
"     14",
"    </a>",
"    ]. The response to antiemetics can be helpful in distinguishing the origin of nausea and vomiting. Antiemetics are usually ineffective in patients who received lethal doses of radiation, whereas they may be helpful in patients who received lower doses. In addition, prodromal nausea and vomiting in patients who are likely to recover may last up to 48 hours (but usually not longer) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of patients exposed to radiation is performed to evaluate the biologic effects of radiation and to prepare for therapies that may be necessary (eg, blood transfusion, bone marrow transplantation, fluid and electrolyte therapy). Assay of the biologic effects of radiation helps to refine the clinical estimates of initial dose of radiation received and better prepare for potential sequelae and complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBC with differential &ndash; A complete blood count with differential should be obtained in all patients with suspected radiation injury at the time of presentation and every six hours for 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/8\">",
"       8",
"      </a>",
"      ]. The absolute lymphocyte count can be used to estimate the initial radiation dose and the severity of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/8\">",
"       8",
"      </a>",
"      ]. The venipuncture should be performed at a noncontaminated site (if possible); the puncture site should be covered after the procedure.",
"     </li>",
"     <li>",
"      Cytogenetic studies &ndash; The observed levels of dicentrics (chromosomes with two centromeres) after arrest in first metaphase also can be related to dose via an established dose-response calibration curve [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. As soon as practical after the irradiation event, 10 to 15 mL of peripheral blood should be collected in a heparinized blood collection tube and immediately transported (under refrigeration) to the cytogenetic laboratory for processing.",
"     </li>",
"     <li>",
"      Electrolytes &ndash; Blood chemistries should also be obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,18\">",
"       6,18",
"      </a>",
"      ]. Hyponatremia, hypernatremia, hypokalemia, and acidosis may be caused by massive loss of fluid and electrolytes through the gastrointestinal tract. Chemistries should be monitored daily unless the patient's clinical condition requires more frequent monitoring.",
"     </li>",
"     <li>",
"      Blood and human leukocytes antigen typing &ndash; Because blood transfusions and, possibly, hematopoietic stem cell transplantation may be required to treat the effects of radiation on the bone marrow, type and crossmatch and blood for human leukocyte antigen (HLA) typing should be obtained; the sample for HLA typing should be obtained before the lymphocyte count falls.",
"     </li>",
"     <li>",
"      Urinalysis &ndash; Patients with suspected radiation injury also should have a baseline urinalysis at the time of presentation, daily urinalysis with microscopy, and strict monitoring of urine output to evaluate radiation-induced changes in kidney function. If renal impairment develops, consultation with a nephrologist should be arranged; rare patients may require long-term dialysis or renal transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All samples should be placed in separate containers that are labeled with the patient's name, date, and details of the sample (eg, time, site). Appropriate advice (eg, legal, radiation safety) regarding the storage and disposition requirements of collected samples should be obtained and followed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;External contamination occurs when material that contains radioactive atoms is deposited on skin, clothing, or other surfaces. Because persons contaminated with radioactive materials are exposed to radiation until the source of radiation is removed, decontamination should occur as soon as possible after life- and limb-threatening conditions are addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. Medical staff who care for contaminated patients, particularly at the accident site, must take precautions to avoid irradiating themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Radiation safety'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     External",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child who is externally contaminated with radioactive particles should have all clothing removed, preferably at the scene of the accident. This procedure will usually remove most of the radioactive particles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ]. Clothing should be placed in labeled plastic bags. Equipment that was used to transport the patient, and any ambulance equipment that may have had contact with the patient, should remain separate from the receiving hospital equipment until the transport equipment can be surveyed for radiation and decontaminated if necessary. At the receiving hospital, the contaminated patient should be treated in an area that is separate from the rest of the treatment center, or in an area that is clearly marked as contaminated if such an area is available. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment area'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radiation survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once he or she is medically stabilized, the patient should be surveyed with alpha and Geiger counters to evaluate for radioactivity, which if present should be documented on an anatomic chart (",
"    <a class=\"graphic graphic_figure graphicRef67746 graphicRef81708 \" href=\"UTD.htm?13/16/13576\">",
"     figure 1A-B",
"    </a>",
"    ). This information is then used to determine the sequence of decontamination of intact skin. To assess the possibility of internal contamination, separate saline- or water-moistened swabs should be used to wipe the skin, nares, ears, mouth, and wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ]. These swabs should be placed in bags, labeled with the anatomic collection site, and assessed for radioactivity with a Geiger counter or alpha-radiation detection device [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decontamination should begin with debridement of open wounds to remove as much debris as possible. Metallic fragments can be highly radioactive and should be removed with tongs or forceps (to increase the distance to the exposure source) rather than the fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. The debris should be stored in lead containers and surveyed for radioactivity. Wounds should then be copiously irrigated with normal saline until they are free of radioactivity, and then covered with a waterproof dressing. Contaminated burns should be treated as any other thermal or chemical burn [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/7\">",
"     7",
"    </a>",
"    ]; contaminants may slough off with the burn eschar, leading to contamination of dressings and bed linens, which should be handled accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mouth, nose, eyes, and ears require special attention in decontamination because of the potential for more rapid absorption of radioactive material [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent mouth rinsing and tooth brushing with toothpaste are encouraged if radioactive material has entered the oral cavity; gargling with a 3 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      solution also may be helpful. Gastric lavage may be indicated if radioactive materials were swallowed.",
"     </li>",
"     <li>",
"      If the eyes have been contaminated, they should be rinsed by directing a stream of water from the inner canthus to the outer canthus. Care should be taken to avoid contamination of the nasolacrimal duct.",
"     </li>",
"     <li>",
"      If the auditory canals have been contaminated and the tympanic membrane is intact, an ear syringe can be used to rinse the auditory canal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decontamination should then proceed from areas with highest to lowest radioactivity. Decontamination should be performed with sponging of lukewarm water and a mild soap. Cold water should be avoided because it closes the pores and can trap radioactive materials; hot water should be avoided because it opens the pores and causes vasodilation, increasing the risk of absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ]. Care should be taken to avoid further abrasion or erythema of the skin, which also may increase absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,12,18\">",
"     6,12,18",
"    </a>",
"    ]. Areas that are sponged should be resurveyed every three to five minutes until the counts are consistent with background levels. To obtain accurate results, contaminated drapes and dressings should be removed before each episode of monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Hot\" particles are microscopic particles that can be highly radioactive and difficult to detect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dislodge [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. Such particles can sometimes be localized by placing a thick piece of lead between the suspected site and the radiation detector; if the particle is properly localized, the radiation count should decrease. Localized particles can usually be removed by mechanical means, although sometimes punch biopsy of the skin is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. Hair may need to be clipped if washing is insufficient for decontamination; it should not be shaved, since shaving may increase absorption. The liquids and materials used for decontamination should be stored in marked containers for disposal.",
"   </p>",
"   <p>",
"    After decontamination, the patient should be dried and placed on a clean stretcher or in a wheelchair that is pushed by an individual who was not involved in the decontamination. The patient can then be evaluated by emergency department personnel for further care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All equipment used in decontamination should be surveyed before leaving the decontamination area. Individuals who leave the decontamination area should follow a clearly marked path in order to minimize cross-contamination. Personnel leaving the decontamination area should deposit all gloves, masks, hats, scrub suits, and shoe covers into marked, designated receptacles before leaving. The radiation safety specialist should collect dosimeters after they have been labeled with appropriate identifying information [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6,12,18,19\">",
"     6,12,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Internal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency department personnel must intervene quickly to prevent radioactive elements from being incorporated into the body, a process that can occur within minutes. If the radiation accident involved an explosion or fire, inhalation (and incorporation) of radioactive material should be assumed, and the patient treated accordingly. Patients with external contamination who have undergone endotracheal intubation also are considered to have internal contamination and should be managed similarly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/21\">",
"     21",
"    </a>",
"    ]. Decontamination of the mouth, eyes, and ears is discussed above. Once external decontamination is complete, patients with internal contamination usually pose no hazard to caregivers or to the medical facility, although their fecal and urinary excretion products should be measured for radioactivity and disposed of in marked, sealed containers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Radiation survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioassay and whole body counting can assist in determining the magnitude of contamination and response to therapy. To assess the possibility of internal contamination, separate saline- or water-moistened cotton-tipped applicators should be used to swab the skin, nares, ears, mouth, and wounds before and after decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ]. These swabs should be placed in bags, labeled with the anatomic collection site, and assessed for radioactivity with a Geiger counter or alpha-radiation detection device [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ]. If these samples have radioactivity in excess of background, incorporation of radioactive material through ingestion, inhalation, or absorption is possible.",
"   </p>",
"   <p>",
"    If internal contamination has occurred or is suspected, samples of feces, urine, wound secretions, or emesis should be obtained as soon as possible upon arrival to the treating facility. Urine and feces should continue to be tested for four days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ]. If internal contamination has occurred, urine and feces may contain radioactive material, creating a potential contamination hazard, and appropriate precautions must be taken [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of management are to limit exposure and reduce further damage to the child's rapidly proliferating cellular systems [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/12\">",
"     12",
"    </a>",
"    ]. Absorption can be prevented by several methods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/9,19,22\">",
"     9,19,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forming a complex with the substance",
"     </li>",
"     <li>",
"      Binding the substance in a resin",
"     </li>",
"     <li>",
"      Reducing absorption from the bowel",
"     </li>",
"     <li>",
"      Facilitating elimination by decreasing bowel transit time or forcing diuresis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isotope identification is necessary before directed treatment. Isotope identifiers are available from state radiation departments, National Guard Civil Support Teams, and some HazMat units.",
"   </p>",
"   <p>",
"    Hospitals that are designated as the receiving centers for radiation accidents at facilities that handle nuclear materials (eg, laboratories, industry) should have rapid access to chelating agents, some of which are available only by FDA protocol. Information regarding these agents, as well as expert guidance about the management of internal contamination, is available at",
"    <a class=\"external\" href=\"file://orise.orau.gov/reacts/\">",
"     file://orise.orau.gov/reacts/",
"    </a>",
"    ,the National Council on Radiation Protection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/23\">",
"     23",
"    </a>",
"    ], poison control centers, or by calling",
"    <span class=\"nowrap\">",
"     REAC/TS",
"    </span>",
"    at its 24-hour emergency number (865-576-1005).",
"   </p>",
"   <p>",
"    Specific management of internal contamination depends upon the radioactive element involved and its chemical form. The following information is also summarized in a table that is available at",
"    <a class=\"external\" href=\"file://orise.orau.gov/files/reacts/medical-aspects-of-radiation-incidents.pdf\">",
"     file://orise.orau.gov/files/reacts/medical-aspects-of-radiation-incidents.pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who were potentially exposed to radioactive iodine should be treated with supersaturated potassium to block thyroid deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/9,19,22\">",
"       9,19,22",
"      </a>",
"      ]. When administered immediately before, and 2, 8, and 24 hours after exposure,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=see_link\">",
"       potassium iodide",
"      </a>",
"      prevents 100, 80, 40, and 7 percent, respectively, of the radioiodine deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/24\">",
"       24",
"      </a>",
"      ]. Because potassium iodide works best when administered near the time of exposure, it should be available in homes, schools, and day care settings, particularly those that are located near nuclear power plants (within a 10-mile radius) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/2,7,25\">",
"       2,7,25",
"      </a>",
"      ]. Information on dosage and available preparations for children can be found at",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm\">",
"       file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link&amp;anchor=H16#H16\">",
"       \"Radiation-induced thyroid cancer\", section on 'Potassium iodide for thyroid protection in a nuclear accident'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with potential incorporation of the transuranics (eg, plutonium-239 or yttrium-90) can receive calcium or zinc diethylene triamine penta-acetate (DTPA) for chelation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      can be helpful in alkalinizing the urine of patients contaminated with uranium to reduce the risk of acute tubular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/9,19\">",
"       9,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prussian blue (ferrihexacyano-ferrate II) should be administered to patients contaminated with substances, such as cesium-137, rubidium-82, or thallium-201, to prevent recycling of the radioactive substance [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral calcium or aluminum phosphate solutions can block the absorption of strontium through competitive inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/9,19,22\">",
"       9,19,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     IRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who were exposed only to gamma radiation pose no risk of contamination to medical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"     6",
"    </a>",
"    ]. They should be treated as all other trauma victims: life-threatening injuries should be stabilized before radiation exposure is addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Partial-body exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute partial-body exposure, one part of the body receives the majority of exposure. This type of injury comprises the majority of gamma radiation exposure incidents, usually from industrial accidents in which radioactive sources were handled inappropriately. Decontamination should be performed as needed (ie, if the patient was also exposed to alpha or beta particles).",
"   </p>",
"   <p>",
"    The skin is the area the most commonly involved. Patients who received partial-body doses less than 500 rad (5 Gy) usually have damage limited to erythema, severe xerosis, vesiculation, and loss of hair with eczematous changes that may be permanent. Healing is delayed and may take one to two months. These injuries may need to be treated at a center that specializes in burns.",
"   </p>",
"   <p>",
"    In patients who received partial-body doses greater than 500 rad (5 Gy), wet gangrene and ulceration may develop caused by damage to the underlying vasculature and connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/26\">",
"     26",
"    </a>",
"    ]. Management of these types of injuries requires consultation and close coordination between burn specialists, plastic surgeons, orthopedists, occupational and physical therapists, orthotists, and psychologists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute radiation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for patients who have been exposed to large doses (&gt;200 rad [2 Gy]) of whole-body radiation is based upon the symptoms, which usually begin between 21 and 60 days after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. Consultation with experts in radiation accident management is encouraged and is available through",
"    <span class=\"nowrap\">",
"     REAC/TS",
"    </span>",
"    (",
"    <a class=\"external\" href=\"file://orise.orau.gov/reacts/\">",
"     file://orise.orau.gov/reacts/",
"    </a>",
"    ; telephone: 865-576-1005 or 865-576-3131) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hematopoietic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;To monitor the hematopoietic effects of radiation exposure, a complete blood count with differential should be obtained at the time of presentation and repeated every six hours for 24 to 48 hours to monitor the trend. The lymphocyte count at 48 hours can be used to estimate the initial exposure dose and prognosis. If the dose of radiation exceeded 500 rad (5 Gy) or the 48-hour lymphocyte count drops below 500, the exposed patient should be transferred to a tertiary care facility with capabilities for bone marrow transplant, since survival without such a procedure is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms requiring treatment (eg, bleeding, anemia) may not develop until 21 to 30 days after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/20\">",
"     20",
"    </a>",
"    ]. The management is centered on the control of bleeding and anemia; blood products should be transfused as necessary. Hematology consultation should be obtained to assist with life-threatening neutropenia. The use of granulocyte-colony stimulating factor may help speed recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. The administration of broad-spectrum antibiotics is necessary to prevent death from an overwhelming infection in patients who develop fever. Prophylaxis against viral infections may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     GI syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal manifestations of radiation exposure depend upon the absorbed dose. At low doses (150 rad [1.5 Gy]), only the prodromal phase of nausea, vomiting, and gastric suppression are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/28\">",
"     28",
"    </a>",
"    ]. At doses greater than 200 rad (2 Gy), the gastrointestinal syndrome typically manifests within five days of initial exposure (following the prodromal phase and a short latent phase) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. More severe symptoms of gastrointestinal tract damage develop at doses greater than 600 to 800 rad (6 to 8 Gy), and doses greater than 1000 to 1200 rad (10 to 20 Gy) may cause death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Explosive vomiting and bloody diarrhea occur as the gastrointestinal epithelium is shed, the intestinal crypts and mucosal barrier are destroyed, and intestinal motility is disrupted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/28\">",
"     28",
"    </a>",
"    ]. Severe electrolyte imbalance and hypovolemic shock may result. In addition, the disruption of the mucosal barrier permits bacteria to enter the systemic circulation, which, when combined with the depleted immune system, markedly increases the risk of death from sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aggressive fluid resuscitation with continual monitoring of serum chemistries and fluid balance is crucial for patients with the gastrointestinal syndrome, since life-threatening electrolyte disturbances will occur. Antiemetic and antidiarrheal agents should be used liberally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/18\">",
"     18",
"    </a>",
"    ]. Consultation with gastroenterologists should be obtained, and parenteral nutrition should be initiated to promote tissue anabolism. Antibiotics are necessary for treatment if bacteremia develops. Despite these measures, the onset of fever usually precedes irreversible septic shock that unfortunately remains the overwhelming cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/18,26\">",
"     18,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     CNS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients exposed to doses of radiation that are high enough to cause the CNS syndrome have an extremely poor prognosis. In mass casualty situations, the treatment of these victims is dependent upon the availability of resources and potential for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of radiation accidents experience a great deal of psychologic stress related to perceived radiation injury and concern about future cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/7,20,30\">",
"     7,20,30",
"    </a>",
"    ]. All victims, regardless of the degree of exposure, should have follow-up arranged with providers who can address these concerns (eg, environmental health or radiation specialists, psychologists, primary care physicians).",
"   </p>",
"   <p>",
"    Children who received radiation exposure to the thyroid gland should have their thyroid glands checked regularly. The frequency and method of follow-up of irradiated patients depends upon their estimated risk and the clinical findings at the initial evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation-induced thyroid cancer\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ocular exposure, particularly to neutron radiation, should undergo regular examination for cataract development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25193/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7584026\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further guidance on the management of radiation exposure in children is available as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      United States Health and Human Services: Radiation Emergency Medical Management &ndash; This website provides comprehensive guidance on diagnosis and treatment of a wide variety of radiation emergencies including nuclear reactor accidents, nuclear explosions, and radiological dispersal devices (eg, dirty bomb) at",
"      <a class=\"external\" href=\"file://www.remm.nlm.gov/\">",
"       www.remm.nlm.gov",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Oak Ridge Institute for Science and Education (ORISE) &ndash; Hospital triage and medical aspects of radiation incidents, including detailed procedure demonstrations for decontamination are available at",
"      <a class=\"external\" href=\"file://orise.orau.gov/reacts/resources/default.aspx\">",
"       file://orise.orau.gov/reacts/resources/default.aspx",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Food and Drug Administration &ndash; Information on dosage and available preparations (including instructions on how to mix the tablets with food or drink to make them palatable for infants and small children) can be found at",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm\">",
"       file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      World Health Organization (WHO) &ndash; WHO maintains a website that provides useful information and documents for download in the event of an international radiation accident or emergency at",
"      <a class=\"external\" href=\"file://www.who.int/ionizing_radiation/a_e/en\">",
"       www.who.int/ionizing_radiation/a_e/en",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Regional poison control centers &ndash; In the United States, regional poison control centers are available to provide radiation exposure information and resources (eg, access to local radiation safety officers). To obtain emergency consultation, call 1-800-222-1222. The World Health Organization maintains a list of international poison centers at",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13585031\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13585195\">",
"    <span class=\"h2\">",
"     Radiation safety",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protection from radiation exposure is accomplished through (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment planning'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Minimizing the time of exposure",
"     </li>",
"     <li>",
"      Maximizing the distance from the radiation source (if possible)",
"     </li>",
"     <li>",
"      Using a shield as appropriate (eg, sheltering in place in the basement of a home or other building)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evacuation of an exposed region is the most effective means of reducing radiation exposure in a community. Sheltering in place is the main alternative if timely evacuation is not possible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Communities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All health care facilities should have a written radiation disaster plan that is known and rehearsed by hospital staff and maintain ready access to the supplies and equipment necessary in the management of radiation accidents (",
"      <a class=\"graphic graphic_table graphicRef71406 \" href=\"UTD.htm?41/28/42443\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Health care facilities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13585203\">",
"    <span class=\"h2\">",
"     Management: irradiation with contamination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of life- and limb-threatening conditions while minimizing radiation exposure to health care workers and contamination of the health care facility is the first priority in the management of children who are exposed to radiation. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A radiation safety officer at the receiving facility should be notified and made responsible for monitoring radiation levels, overseeing the storage and disposal of decontaminated materials (eg, irrigation solutions, contaminated bedding and clothing, exposed patients&rsquo; urine and feces), and ensuring that contamination is eliminated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initial stabilization, decontamination begins by having externally contaminated patients remove all clothing followed by a radiation survey using alpha and Geiger counters to identify and document areas of heaviest contamination (",
"      <a class=\"graphic graphic_figure graphicRef67746 graphicRef81708 \" href=\"UTD.htm?13/16/13576\">",
"       figure 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Decontamination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation survey'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decontamination should begin with debridement of open wounds to remove as much debris as possible. Metallic fragments can be highly radioactive and should be removed with tongs or forceps (to increase the distance between the exposure source and the health care provider&rsquo;s fingers) rather than the fingers. Wounds should then be copiously irrigated with warmed, normal saline until they are free of radioactivity, and then covered with a waterproof dressing. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To assess the possibility of internal contamination, separate saline- or water-moistened cotton-tipped applicators should be used to swab the skin, nares, ears, mouth, and wounds before and after decontamination. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Internal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiation survey'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific management of internal contamination depends upon the radioactive element involved and its chemical form. Information regarding these agents, as well as expert guidance about the management of internal contamination, is available at",
"      <a class=\"external\" href=\"file://orise.orau.gov/reacts/\">",
"       file://orise.orau.gov/reacts/",
"      </a>",
"      , the National Council on Radiation Protection, poison control centers, or by calling",
"      <span class=\"nowrap\">",
"       REAC/TS",
"      </span>",
"      at its 24-hour emergency number (865-576-1005). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7584026\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13585564\">",
"    <span class=\"h2\">",
"     Management: irradiation without contamination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who were exposed only to gamma radiation pose no risk of contamination to medical personnel. They should be treated as all other trauma victims: life-threatening injuries should be stabilized before radiation exposure is addressed. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In acute partial-body exposure, one part of the body receives the majority of exposure. Cutaneous findings are typical and the degree of changes depends on the dose of radiation received. Specialized wound care (eg, burn center) is warranted. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Partial-body exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for patients who have been exposed to large doses (&gt;200 rad [2 Gy]) of whole-body radiation is based upon the symptoms, which usually begin between 21 and 60 days after exposure. Consultation with experts in radiation accident management is encouraged and is available through",
"      <span class=\"nowrap\">",
"       REAC/TS",
"      </span>",
"      (",
"      <a class=\"external\" href=\"file://orise.orau.gov/reacts/\">",
"       file://orise.orau.gov/reacts/",
"      </a>",
"      ; telephone: 865-576-1005 or 865-576-3131). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Acute radiation syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7584026\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mettler FA, Royal HD, Drum DE. Radiation accidents. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/2\">",
"      American Academy of Pediatrics Committee on Environmental Health. Radiation disasters and children. Pediatrics 2003; 111:1455.",
"     </a>",
"    </li>",
"    <li>",
"     National Council on Radiation Protection and Measurements. Management of Terrorist Events Involving Radioactive Material. National Council on Radiation Protection and Measurements, Bethesda, MD 2001.",
"    </li>",
"    <li>",
"     American Thyroid Association. American Thyroid Association endorses potassium iodide for radiation emergencies. American Thyroid Association, Falls Church, VA, 2001. www.thyroid.org/professionals/publications/statements/ki/02_04_09_ki_endrse.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/5\">",
"      Vyas DR, Dick RM, Crawford J. Management of radiation accidents and exposures. Pediatr Emerg Care 1994; 10:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/6\">",
"      Leonard RB, Ricks RC. Emergency department radiation accident protocol. Ann Emerg Med 1980; 9:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/7\">",
"      Mettler FA Jr, Voelz GL. Major radiation exposure--what to expect and how to respond. N Engl J Med 2002; 346:1554.",
"     </a>",
"    </li>",
"    <li>",
"     Guidance for Radiation Accident Management. www.orau.gov/reacts/guidance.htm.",
"    </li>",
"    <li>",
"     Shannon BE, Jenkins JL, Braen GR. Radiation Injury. In: Manual of Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.435.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/10\">",
"      Linnemann RE. Medical experience and preparedness for handling radiation injuries. J Med Assoc Ga 1989; 78:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/11\">",
"      Jacob P, Kenigsberg Y, Zvonova I, et al. Childhood exposure due to the Chernobyl accident and thyroid cancer risk in contaminated areas of Belarus and Russia. Br J Cancer 1999; 80:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/12\">",
"      Rutherford, MW, Seward, JP. Radiation injuries and illnesses in pediatric emergency medicine. Clin Pediatr Emerg Med 2001; 2:141.",
"     </a>",
"    </li>",
"    <li>",
"     Sholtis J. Ionizing radiation and their interactions with matter. In: Military Radiobiology, Conklin JJ, Walker RI (Eds), Academic Press, Orlando 1987. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/14\">",
"      Darte JM, Little WM. Management of the acute radiation syndrome. Can Med Assoc J 1967; 96:196.",
"     </a>",
"    </li>",
"    <li>",
"     Jones F. Neuropsychiatric casualties of nuclear, biological, and chemical warfare. In: Textbook of Military Medicine, Zajtchuk R (Ed), Office of the Surgeon General, Washington DC 1995. p.98.",
"    </li>",
"    <li>",
"     Jarrett, DG. Medical management of radiological casualities. Military Medical Operations Office. Armed Forces Radiobiology Research Institute. Bethesda, MD 1999. www.afrri.usuhs.mil.",
"    </li>",
"    <li>",
"     Littlefield LG, Joiner EE, DuFrain RJ, et al. Cytogenetic dose estimates from in vivo samples from persons involved in real or suspected radiation exposures. In: The Medical Basis of Radiation Accident Preparedness, Hubner KF, Fry SA (Eds), Elsevier, North Holland 1980. p.375.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/18\">",
"      Reeves GI. Radiation injuries. Crit Care Clin 1999; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     Guidance for Radiation Accident Management. www.orau.gov/reacts/guidance.htm (Accessed on December 07, 2005).",
"    </li>",
"    <li>",
"     Mettler FA, Royal HD, Drum DE. Radiation accidents. In: Textbook of Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/21\">",
"      Fong F, Schrader DC. Radiation disasters and emergency department preparedness. Emerg Med Clin North Am 1996; 14:349.",
"     </a>",
"    </li>",
"    <li>",
"     Asch SM. Radiation exposure. In: Pediatric Emergency Medicine: Concepts and Clinical Practice, Barkin RM, Caputo GL, Jaffe DM, et al (Eds), Mosby, St. Louis 1997. p.522.",
"    </li>",
"    <li>",
"     Management of Persons Contaminated with Radionuclides: Handbook. NRCP report no. 161, National Council on Radiation Protection and Measurement; Bethesda, MD, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/24\">",
"      Zanzonico PB, Becker DV. Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout. Health Phys 2000; 78:660.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration, Home preparation procedure for emergency administration of potassium iodide tablets to infants and children using 130 milligram (mg) tablets. www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072254.htm (Accessed on June 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/26\">",
"      Conklin JJ, Walker RI, Hirsch EF. Current concepts in the management of radiation injuries and associated trauma. Surg Gynecol Obstet 1983; 156:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/27\">",
"      Saenger EL. Radiation accidents. Ann Emerg Med 1986; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/28\">",
"      Dubois A, Walker RI. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome. Gastroenterology 1988; 95:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/29\">",
"      Gale RP. Medical response to radiation and nuclear accidents: lessons for the future. J Natl Cancer Inst 1988; 80:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25193/abstract/30\">",
"      Becker SM. Psychosocial assistance after environmental accidents: a policy perspective. Environ Health Perspect 1997; 105 Suppl 6:1557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6588 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25193=[""].join("\n");
var outline_f24_38_25193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13585031\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiation safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Communities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Health care facilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment area",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      External",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radiation survey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Internal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Radiation survey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Partial-body exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute radiation syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hematopoietic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - GI syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - CNS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7584026\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13585031\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13585195\">",
"      Radiation safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13585203\">",
"      Management: irradiation with contamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13585564\">",
"      Management: irradiation without contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6588|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/38/38510\" title=\"figure 1A\">",
"      Radiation survey documentation A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44534\" title=\"figure 1B\">",
"      Radiation survey documentation B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/28/42443\" title=\"table 1\">",
"      Decontamination supplies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/47/11005\" title=\"table 2\">",
"      Common radioactive isotopes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=related_link\">",
"      Clinical features of radiation exposure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=related_link\">",
"      Treatment of radiation injury in the adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_38_25194="Epidemiology and etiologic associations of hepatocellular carcinoma";
var content_f24_38_25194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and etiologic associations of hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Jonathan M Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Robert L Carithers, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/38/25194/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/38/25194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) results in between 250,000 and one million deaths globally per annum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. HCC has unique geographic, sex, and age distributions that are likely determined by specific etiologic factors.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and etiologic associations of HCC. Surveillance recommendations, clinical manifestations, diagnosis, and management of HCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver cancer in men is the fifth most frequently diagnosed cancer worldwide, and is the second leading cause of cancer-related death in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"     5",
"    </a>",
"    ]. In women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death. In the United States, liver cancer is the ninth leading cause of cancer death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/6\">",
"     6",
"    </a>",
"    ]. The number of deaths per year in HCC is virtually identical to the incidence throughout the world, underscoring the high case fatality rate of this aggressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"     5",
"    </a>",
"    ]. Almost 80 percent of cases are due to underlying chronic hepatitis B and C virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146270472\">",
"    <span class=\"h2\">",
"     Geographic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HCC varies widely according to geographic location (",
"    <a class=\"graphic graphic_table graphicRef50081 \" href=\"UTD.htm?11/10/11438\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"     5",
"    </a>",
"    ]. The distribution of HCC also differs among racial and ethnic groups within the same country, and between regions within the same country [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/1\">",
"     1",
"    </a>",
"    ]. These extreme differences in distribution of HCC are probably due to regional variations in exposure to hepatitis viruses and environmental pathogens. As an example, the frequency of hepatitis B virus carriers is relatively high in the high-incidence regions and low in the low-incidence regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-incidence regions (more than 15 cases per 100,000 population per year) include sub-Saharan Africa, the People's Republic of China, Hong Kong, and Taiwan [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/1\">",
"       1",
"      </a>",
"      ]. The incidence is",
"      <span class=\"nowrap\">",
"       24.2/100,000",
"      </span>",
"      in parts of Africa, and",
"      <span class=\"nowrap\">",
"       35.5/100,000",
"      </span>",
"      in Eastern Asia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/8\">",
"       8",
"      </a>",
"      ]. Over 40 percent of all cases of HCC occur in the People's Republic of China, which has an annual incidence of 137,000 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/9\">",
"       9",
"      </a>",
"      ]. Japan has had one of the highest incidence rates of HCC associated with chronic HCV infection; however, the incidence appears to be decreasing in recent years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intermediate-incidence areas include several countries in Eastern and Western Europe, Thailand, Indonesia, Jamaica, Haiti, New Zealand (Maoris), and Alaska (Eskimos) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      North and South America, most of Europe, Australia and parts of the Middle East are low-incidence areas with fewer than three cases reported per 100,000 population per year. However, the incidence in the United States has increased during the past two decades, possibly due to a large pool of people with longstanding chronic hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The rate began to accelerate in the mid 1980s, most likely because of the increased incidence of cirrhosis due to chronic HCV infection and nonalcoholic fatty liver disease, combined with a large influx of immigrants from East Asia and other geographic areas with high endemic rates of hepatitis B viral infection [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liver cancer incidence rates are increasing in many parts of the world, including the United States and central Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A total of 48,596 cases of HCC were reported in the United States between 2001 to 2006 according to data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute and the National Program of Cancer Registries from the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence in the United States was estimated to be 3.0 per 100,000, which represents an increase of 3.5 percent (from 2.7 to 3.2 per 100,000 from 2001 to 2006). The incidence of HCC in the United States is expected to continue to rise as a consequence of high hepatitis C infection rates between 1960 and 1990 and the average 20 to 30 year lag time between virus acquisition and the development of cirrhosis and carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sex and age distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all parts of the world, men are more likely than women to develop HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"     5",
"    </a>",
"    ]. The disparity is more pronounced in high-incidence regions, where men are affected 2.1 to 5.7 times more frequently than women (mean 3.7:1). The ratio decreases to a mean of 2.4:1 in intermediate-incidence areas, and is lower in low-incidence regions. In Northern America, the incidence rates for males and females were 6.8 and 2.2 per 100,000 persons, respectively, in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"     5",
"    </a>",
"    ]. Although not fully understood, the differences in sex distribution are thought to be due to variations in hepatitis carrier states, exposure to environmental toxins, and the trophic effect of androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of HCCs occur in patients with chronic liver disease or cirrhosis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Chronic hepatitis and cirrhosis'",
"    </a>",
"    below.) Thus, older patients with longstanding liver disease are more likely to develop HCC. Several large prospective studies conducted in both Asia and Western Europe have noted a mean age at presentation between 50 and 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In sub-Saharan Africa, however, the mean age of presentation of HCC is decreasing, with a mean age of 33 years at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Racial and ethnic variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based study in the United States identified racial and ethnic variations in the incidence of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/21\">",
"     21",
"    </a>",
"    ]. The incidence was highest among Asians, nearly double that of white Hispanics (11 versus 6.8 per",
"    <span class=\"nowrap\">",
"     100,000/year)",
"    </span>",
"    and four times higher than Caucasians (2.6 per",
"    <span class=\"nowrap\">",
"     100,000/year).",
"    </span>",
"    In another database analysis from the United States, the incidence rates among",
"    <span class=\"nowrap\">",
"     Asians/Pacific",
"    </span>",
"    Islanders, blacks, Native",
"    <span class=\"nowrap\">",
"     Americans/Alaska",
"    </span>",
"    Natives, and whites were 7.8, 4.2, 3.2 and 2.6 per 100,00 persons, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/16\">",
"     16",
"    </a>",
"    ]. The reasons for these differences are likely related to the underlying cause of liver disease, genetic, and environmental factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of important risk factors for the development of hepatocellular carcinoma (HCC) have been identified. These include hepatitis B viral infection , chronic hepatitis C virus (HCV) infection, hereditary hemochromatosis, and cirrhosis of almost any cause [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/12\">",
"     12",
"    </a>",
"    ]. Surveillance for HCC is indicated for many patients with disorders that put them at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643912#H61643912\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Patients who require surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At one major referral center in the United States, the most commonly seen risk factors for HCC were HCV infection, alcohol use, and nonalcoholic fatty liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/22\">",
"     22",
"    </a>",
"    ]. However, HCC can also occur in patients without known risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/23\">",
"     23",
"    </a>",
"    ]. The role of HCC surveillance in these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between chronic hepatitis B viral (HBV) infection and HCC has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/17,19,24-27\">",
"     17,19,24-27",
"    </a>",
"    ]. HCC can develop in patients with chronic HBV, even in the absence of cirrhosis. However, 70 to 90 percent of patients with HBV who develop HCC will have cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/28\">",
"     28",
"    </a>",
"    ]. Because of the association of HBV with HCC, screening for HCC is recommended for many patients with hepatitis B. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Chronic hepatitis and cirrhosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643920#H61643920\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Hepatitis B carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to cirrhosis, a number of other factors have been associated with the risk of developing HCC among patients with chronic HBV, including the viral load, the presence of hepatitis B e antigen (HBeAg), and the presence of hepatitis B surface antigen (HBsAg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159004431\">",
"    <span class=\"h3\">",
"     Viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of HCC is much greater in patients with high serum levels of HBV DNA compared with those who have low levels (&lt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef83282 \" href=\"UTD.htm?2/51/2871\">",
"     figure 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. One of the largest studies to demonstrate this relationship was a community-based study in Taiwan that included a cohort of 3653 patients enrolled between 1991 and 1992 who were HBsAg positive and anti-HCV negative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/29\">",
"     29",
"    </a>",
"    ]. HCC developed in 164 patients (4.5 percent) during a mean follow-up of 11 years. At enrollment, the median age of the HBsAg carriers was 45 years; 85 percent were HBeAg negative, 94 percent had normal alanine aminotransferase (ALT) levels, and 2 percent had cirrhosis. A higher incidence of HCC was associated with HBV DNA level at study entry. For patients with an HBV DNA level &lt;300 copies per mL, there were 108 cases per 100,000 person-years (cumulative incidence 1.3 percent), while for those with an HBV DNA level &gt;1 million",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    there were 1152 cases per 100,000 person-years (cumulative incidence 14.9 percent). The HBV DNA level remained an independent predictor of HCC even after adjusting for covariates known to be associated with HCC, such as sex, age, cigarette smoking, alcohol consumption, HBeAg status, serum ALT level, and the presence of cirrhosis at baseline.",
"    <br/>",
"    <br/>",
"    Most of the subjects in this study likely acquired HBV infection perinatally, and the median age at enrollment was 45 years, suggesting that prolonged high levels of HBV replication might be associated with an increased risk of HCC. However, due to the fluctuating nature of chronic HBV infection, the prognostic value of a single high HBV DNA level is limited. As an example, the risk of HCC in a 20-year-old woman who has a single serum HBV DNA measurement of 1 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    is likely very different from that of a 50-year-old man with an HBV DNA level of 1 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    persisting for five decades. Finally, the applicability of these data to HBsAg carriers who acquired HBV as adults is not clear. Currently, it is recommended that patients with high HBV DNA levels and signs of active inflammation (elevated ALT) for several years undergo surveillance for HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643920#H61643920\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Hepatitis B carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159005272\">",
"    <span class=\"h3\">",
"     Active viral replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBeAg positivity, which indicates active viral replication, is also associated with the development of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]. One of the largest prospective studies to address this issue included 11,893 Taiwanese men who were tested for HBsAg and HBeAg at enrollment and then followed for approximately 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/39\">",
"     39",
"    </a>",
"    ]. During follow-up, 111 cases of HCC were detected. The incidence of HCC was significantly higher in patients who were HBsAg and HBeAg positive (1169 per 100,000 patient-years) compared with patients who were only HBsAg positive (324 per 100,000 patient-years) or who were negative for both HBsAg and HBeAg (39 per 100,000 patient-years). The effect of HBeAg status remained an independent predictor after adjusting for important covariates, including HCV status, alcohol intake, and cigarette smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159004439\">",
"    <span class=\"h3\">",
"     Inactive carriers or resolved infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of HCC is also elevated in patients who are HBsAg positive but HBeAg negative (inactive carriers) compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/26,27,33,39,40\">",
"     26,27,33,39,40",
"    </a>",
"    ]. In addition, there is evidence that patients with serologically resolved infections remain at increased risk for HCC.",
"   </p>",
"   <p>",
"    The risk in inactive carriers was examined in a population-based study from Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/27\">",
"     27",
"    </a>",
"    ]. The study included 20,069 participants with HBV, of whom 1932 had serum HBV DNA &lt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    were HBsAg positive, HBeAg negative, HCV negative, and had normal serum ALT levels. These patients were then compared with patients who had similar characteristics, but were HBsAg negative. During an average follow-up of 13 years, the annual incidence of HCC was higher in patients who were HBsAg positive than in controls (0.06 versus 0.02 percent).",
"   </p>",
"   <p>",
"    Despite a generally favorable prognosis, clearance of HBsAg does not preclude the development of cirrhosis or HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The increased risk of HCC among patients with serologically resolved infection was demonstrated in a study that followed 1271 Alaskan Natives with chronic HBV for an average of 20 years. Among patients who cleared their HBV (ie, became HBsAg negative), the incidence of HCC was lower than that of those who remained HBsAg positive (37 versus 196 per 100,000 person-years), but still higher than among the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/43\">",
"     43",
"    </a>",
"    ]. A separate report suggested that the likelihood of developing HCC is greater in those who clear HBsAg when older than age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159005743\">",
"    <span class=\"h3\">",
"     Effect of HBV treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the impact of treatment for chronic HBV on the risk of HCC. Systematic reviews of the available data suggest that the relative risk is reduced by approximately 60 percent following treatment with interferon or nucleos(t)ide derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. However, treatment does not completely eliminate the risk, and the benefit was not seen in patients who developed nucleos(t)ide resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159005636\">",
"    <span class=\"h3\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who are HBsAg positive appear to be at increased risk for HCC compared with women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/33,48\">",
"     33,48",
"    </a>",
"    ]. In a prospective cohort study that followed 23,820 residents of Taiwan who were between the ages of 30 and 65, the cumulative lifetime incidence of HCC for patients who were positive for HBsAg was higher in men than in women (27 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/48\">",
"     48",
"    </a>",
"    ]. Among patients with HCV, the risk was higher, but there was no longer a difference in HCC risk based upon the patient's sex (cumulative incidence of 38 percent for men and 27 percent for women). As seen in other studies, higher viral loads were associated with an increased risk of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146123953\">",
"    <span class=\"h3\">",
"     Coinfection with HCV or HDV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with HCV has also been associated with an increased risk of HCC. Some studies suggest that patients with dual HBV and HCV infection may have a higher rate of HCC compared with patients infected by either virus alone, particularly those who are anti-HCV and HBeAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/37,49,50\">",
"     37,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coinfection with hepatitis D virus (HDV) also appears to increase the risk of HCC among patients with HBV. A retrospective study involving 200 patients with compensated HBV-related cirrhosis, of whom 20 percent were anti-HDV positive, found that HDV infection increased the risk of HCC threefold and mortality twofold [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/51\">",
"     51",
"    </a>",
"    ]. After adjustment for clinical and serological differences at baseline, the estimated five-year risk for developing HCC was 13, 4, and 2 percent for anti-HDV",
"    <span class=\"nowrap\">",
"     positive/HBeAg",
"    </span>",
"    negative, anti-HDV",
"    <span class=\"nowrap\">",
"     negative/HBeAg",
"    </span>",
"    negative, and anti-HDV",
"    <span class=\"nowrap\">",
"     negative/HBeAg",
"    </span>",
"    positive patients, respectively.",
"   </p>",
"   <p>",
"    In a population-based study from Sweden, the risk of HCC was higher among patients coinfected with HBV and HDV compared with those with HBV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/52\">",
"     52",
"    </a>",
"    ]. Among patients with acute HDV infection, the standardized incidence ratio (SIR) was 6.1 (95% confidence interval [CI] 2.8-11.7), and among patients with chronic HDV infection the SIR was 3.9 (95% CI 1.6-7.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159004447\">",
"    <span class=\"h3\">",
"     Other factors associated with HCC in patients with HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors associated with HCC include older age, habitual alcohol consumption, cigarette smoking, elevated serum ALT levels (",
"    <a class=\"graphic graphic_figure graphicRef83282 \" href=\"UTD.htm?2/51/2871\">",
"     figure 1",
"    </a>",
"    ), the presence of core and precore mutations, and coinfection with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/30,31,33,35,37,41,42,53-55\">",
"     30,31,33,35,37,41,42,53-55",
"    </a>",
"    ]. In addition, a study from China suggested that compared with blood group O, male patients with blood group A or B may be at increased risk for HCC, whereas women with blood group AB or B may be at decreased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some populations may have a more benign course of chronic HBV infection. As an example, at least one study suggests a relatively low incidence of HCC among chronic HBV-infected Greenlandic Inuit than in other parts of the world, despite a ninefold increase in risk of HCC in chronically infected patients compared with HBV-negative persons [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/57\">",
"     57",
"    </a>",
"    ]. Among the reasons postulated to explain the lower risk of HCC seen in this chronically HBV-infected cohort are differences in genotype distribution, infection during adolescence and adulthood (compared with perinatal infection), young age, and genetic influences on the immunologic response to HBV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical significance of hepatitis B virus genotypes\", section on 'Hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strong association between chronic HCV infection and HCC has been observed, but the mechanisms involved in carcinogenesis remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Hepatitis C accounts for at least one-third of the cases of HCC in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/12\">",
"     12",
"    </a>",
"    ]. An important clinical observation is that HCC in patients with HCV occurs almost exclusively in patients with advanced stages of hepatic fibrosis or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/61\">",
"     61",
"    </a>",
"    ]. By contrast, HCC can occur without cirrhosis or significant fibrosis in patients with chronic HBV infection.",
"   </p>",
"   <p>",
"    In a prospective cohort study that followed 23,820 residents of Taiwan between the ages of 30 and 65, the cumulative lifetime incidence of HCC for patients with HCV alone was 24 percent for men and 17 percent for women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients who were also positive for hepatitis B surface antigen had a cumulative incidence of 38 percent for men and 27 percent for women. Among patients with HCV, the differences in HCC rates between men and women were not significantly different. In addition, higher viral loads were associated with an increased risk of HCC.",
"   </p>",
"   <p>",
"    It is generally believed that HCC arises in the setting of rapid cellular turnover and the chronic inflammatory state induced by the hepatitis C virus. One theory is that there is an imbalance in the microenvironments and cytokines of livers infected with the hepatitis C virus, leading to increased inflammation and cell turnover, which ultimately causes cirrhosis. Poorly differentiated hepatocytes likely proliferate and develop into dysplastic nodules and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/62\">",
"     62",
"    </a>",
"    ]. In support of this hypothesis is the observation that HCV-induced HCC correlates well with the degree of inflammation and necrosis, and seems to be caused by inflammation rather than specific oncogene activation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. By contrast, hepatitis B-related HCC, does not correlate as well with inflammation, and there appear to be specific oncogenes induced by the virus that result in an increased risk of HCC.",
"   </p>",
"   <p>",
"    The degree of inflammation in the liver of patients with HCV also correlates with prognosis once HCC is diagnosed. Several oxidative stress and inflammation markers, including CD68+ cells, 8-hydroxydeoxyguanosine (8-OHdG) DNA adducts, and 4-hydroxynonenal (HNE) protein adducts, have been examined in noncancerous liver tissue in patients who had both HCV and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients with higher levels of these markers were found to have a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/65\">",
"     65",
"    </a>",
"    ]. The host immune response may also be an important factor associated with a risk for progression to cirrhosis and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other factors have been implicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal models have suggested that increased hepatic iron stores observed in chronic HCV infection result in increased reactive oxygen species, leading to increased inflammation and cell turnover [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis found an association with HCV genotype 1b, but data from individual studies are mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/68-71\">",
"       68-71",
"      </a>",
"      ] and this association has not been confirmed.",
"     </li>",
"     <li>",
"      Concomitant heavy alcohol use, diabetes mellitus, and obesity were found in various reports to increase the risk of HCC. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tobacco and alcohol abuse'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      HCC was associated with older age, black race, lower platelet count, higher alkaline phosphatase, presence of esophageal varices, and smoking in a report from the HALT-C trial, a prospective study which was designed to evaluate the impact of long-term low dose peginterferon in patients with advanced fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/61\">",
"       61",
"      </a>",
"      ]. Although more common in patients with cirrhosis, HCC also developed in patients with bridging fibrosis.",
"     </li>",
"     <li>",
"      Latent HBV infection or exposure to HBV appears to increase the risk of HCC in patients with HCV and cirrhosis in some regions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/72\">",
"       72",
"      </a>",
"      ], but such exposures do not appear to be an important risk factor for HCC among HCV-infected individuals in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of interferon or combination therapy to treat hepatitis C has been associated with a decreased risk of HCC; benefits have been noted particularly among those achieving a sustained virologic response (ie, viral clearance) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/47,74\">",
"     47,74",
"    </a>",
"    ]. In a meta-analysis of observational studies, patients who achieved a sustained virologic response had a lower risk of developing HCC than those who were treated but did not achieve a sustained virologic response (relative risk 0.24, 95% confidence interval 0.18-0.31). It appears that much of the residual risk is found in patients who had underlying cirrhosis prior to initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link&amp;anchor=H11#H11\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\", section on 'Prevention of hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic hepatitis and cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic liver disease (chronic hepatitis or cirrhosis) of any cause have an increased risk of developing HCC. On the other hand, many patients (20 to 56 percent) with HCC have previously undiagnosed cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. This has important implications for surgical resection and other forms of treatment of HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compensated cirrhotics are thought to have a 1 to 8 percent annual incidence of HCC (depending upon the etiology of the cirrhosis), and those with chronic hepatitis have an approximate annual risk of 1 percent (",
"    <a class=\"graphic graphic_table graphicRef68371 \" href=\"UTD.htm?37/36/38476\">",
"     table 2",
"    </a>",
"    ). Patients with chronic hepatitis and elevated serum alpha-fetoprotein concentrations have a higher risk of HCC than those with normal values (&lt;20",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic hepatitis or cirrhosis who have hepatitis B, hepatitis C, or hereditary hemochromatosis (HH) have the highest risk of developing HCC. Among patients with HH, HCC is virtually limited to patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. As an example, one study followed 152 patients with HH for 1 to 229 months; HCC developed in 28 of 97 with cirrhosis but in none of 55 without cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/78\">",
"     78",
"    </a>",
"    ]. The risk was increased significantly in patients over age 55 and those with HBsAg positivity and alcohol abuse.",
"   </p>",
"   <p>",
"    A similar relationship to cirrhosis has been reported in patients with primary biliary cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146270166\">",
"    <span class=\"h2\">",
"     Environmental toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two environmental toxins, aflatoxin and contaminated drinking water, may contribute to the pathogenesis of HCC. However, their contribution to the worldwide disease burden of HCC (compared with other risk factors such as HBV infection) is minimal. Furthermore, they are probably not important independent etiologic factors but rather may contribute to HCC development in individuals with other risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146270173\">",
"    <span class=\"h3\">",
"     Aflatoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aflatoxin is a mycotoxin that commonly contaminates corn, soybeans, and peanuts. High rates of dietary aflatoxin intake have been associated with HCC (",
"    <a class=\"graphic graphic_table graphicRef71904 \" href=\"UTD.htm?8/52/9035\">",
"     table 3",
"    </a>",
"    ). As an example, the Penghu Islets in Taiwan have an extremely high incidence of HCC that is not entirely accounted for by the HBV carrier state. In a study in which 20 patients with HCC from this region were compared with 86 age-matched controls, the patients were more likely to have aflatoxin B1-albumin adducts (65 versus 37 percent; adjusted odds ratio 5.5); 94 percent of the patients were HBsAg carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/81\">",
"     81",
"    </a>",
"    ]. In another study from Shanghai, the chance of developing HCC among individuals with HBV and exposure to aflatoxin was 59.4 times the normal population incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of the p53 tumor suppressor gene have been demonstrated in patients with hepatocellular carcinoma who have chronically been exposed to aflatoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Similar findings also have been demonstrated in animal models of hepatocarcinogenesis in which p53 mutations have been observed in laboratory animals exposed to HBV and aflatoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/86\">",
"     86",
"    </a>",
"    ]. The potentiating effect of these risk factors has also been demonstrated in transgenic mice that express hepatitis B surface antigen; in one study, some of these mice were bred to lack one of the p53 alleles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were exposed to aflatoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/87\">",
"     87",
"    </a>",
"    ]. At 13 months of age, high-grade HCC developed in all seven mice with each of the three risk factors compared with 62 percent of mice with both p53 alleles even though they were exposed to aflatoxin and 25 percent of mice lacking one p53 allele but not exposed to aflatoxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146270180\">",
"    <span class=\"h3\">",
"     Contaminated drinking water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies conducted in rural China have noted a higher mortality rate from HCC among people who drink pond-ditch water compared with those who drink well water (100 versus fewer than 20 deaths per 100,000 population per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/88\">",
"     88",
"    </a>",
"    ]. The blue-green algal toxin Microcystin commonly contaminates these ponds and is thought to be a strong promoter of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146270187\">",
"    <span class=\"h3\">",
"     Betel nut chewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case control trials have suggested that Betel nut chewing, which is widespread in certain regions of Asia, may be an independent risk factor for the development of cirrhosis and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. It has also been implicated in the development of esophageal and squamous cell head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tobacco and alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking has been shown to be a risk factor for HCC in some [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/93-95\">",
"     93-95",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. Alcohol intake has been linked to HCC in many reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/95-101\">",
"     95-101",
"    </a>",
"    ], although the threshold dose and duration of use are unclear. The relationship between ethanol and HCC could be a direct toxic effect, or an indirect one, since alcohol represents an important risk factor for cirrhosis, a predisposing factor for HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concomitant heavy alcohol use, diabetes mellitus, and obesity were found in various reports to increase the risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/72,102-105\">",
"     72,102-105",
"    </a>",
"    ]. The risk of alcohol-induced HCC can be modified by the presence of viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/99,106,107\">",
"     99,106,107",
"    </a>",
"    ]. As an example, in an Italian case control study that included 464 subjects with HCC and 824 controls, there was a linear increase in the odds ratio of HCC for increasing alcohol intake over 60 grams daily, which was further increased by a factor of two in patients infected with either HBV or HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies suggest a possible link between diabetes mellitus and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/108-115\">",
"     108-115",
"    </a>",
"    ], and multiple systemic reviews and meta-analyses have also found an association [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. A systematic review that included a total of 49 case-control and cohort studies estimated that the risk was increased by approximately 2.2-fold (risk ratio 2.2; 95% CI 1.7-3.0), although few studies adjusted for diet and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/116\">",
"     116",
"    </a>",
"    ]. A meta-analysis of 14 prospective epidemiologic studies also found an increased risk of HCC among patients with diabetes (relative risk 1.9; 95% CI 1.2-2.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/117\">",
"     117",
"    </a>",
"    ]. In addition, a study found that the presence of the metabolic syndrome (defined by the presence of three of the following: elevated waist",
"    <span class=\"nowrap\">",
"     circumference/central",
"    </span>",
"    obesity, dyslipidemia, hypertension, and impaired fasting glucose) was a risk factor for HCC (adjusted odds ratio 2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large population-based cohort study confirmed the findings of the systematic review and meta-analysis. The study included 19,349 patients with newly diagnosed diabetes and 77,396 patients without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/111\">",
"     111",
"    </a>",
"    ]. The incidence of HCC was significantly higher among patients with diabetes compared with those without diabetes (21.0 versus 10.4 per 10,000 person-years), with an adjusted hazard ratio [HR] of 1.7 (95% CI 1.5-2.0). The use of a thiazolidinedione or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was associated with a decreased risk of HCC among patients with diabetes (adjusted HR 0.56 and 0.49, respectively). Similarly, in a large case-control study, the use of metformin among patients who were diabetic was associated with a 7 percent per year reduction in the risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, associations between diabetes and HCC should be interpreted with caution. In many cases, the onset of glucose intolerance results from the development of cirrhosis, so \"diabetes\" in this context may be a surrogate for cirrhosis, which increases the risk of HCC. In addition, many patients with diabetes also have nonalcoholic fatty liver disease (NAFLD), which has also been associated with an increased risk of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9507724\">",
"    <span class=\"h2\">",
"     Nonalcoholic fatty liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing evidence that NAFLD represents an increasingly frequent underlying liver disease in patients with HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/120-123\">",
"     120-123",
"    </a>",
"    ]. It is likely that NAFLD causes HCC via cirrhosis, although the exact pathogenesis has not yet been determined. One study found that HCC in NASH was associated with obesity, diabetes, hypertension and male sex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=see_link\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of HCC in patients with hemochromatosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alpha-1 antitrypsin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-1 antitrypsin deficiency has been associated with an increased risk of HCC, which can occur in patients without cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Epidermal growth factor polymorphisms and receptor expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain polymorphisms of the epidermal growth factor (EGF) gene have been associated with an increased risk of HCC in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. In addition, the receptor for EGF is a cofactor for HCV entry into cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/126\">",
"     126",
"    </a>",
"    ]. Overexpression of epidermal growth factor in the liver has been associated with HCC in animal models, providing a rationale for the observed association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20494509\">",
"    <span class=\"h2\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of red meat and saturated fat has been associated with an increased risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/127,128\">",
"     127,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170508916\">",
"    <span class=\"h1\">",
"     PROTECTIVE FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170508993\">",
"    <span class=\"h2\">",
"     Statin use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin use has been associated with a lower risk of HCC. This was demonstrated in a population-based study from China that included 33,413 patients with HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/129\">",
"     129",
"    </a>",
"    ]. During 328,946 person-years of follow-up, 1021 HCCs developed (310 per 100,000 person-years). There was a decreased risk of HCC among patients using statins, with a dose-response seen. Compared with patients who did not use statins, patients with 28 to 90 cumulative defined daily doses (cDDDs) of a statin had a hazard ratio (HR) for HCC of 0.66 (95%CI 0.44-0.99), those with 91 to 365 cDDDs had an HR of 0.41 (95% CI 0.27-0.61), and those with &gt;365 cDDDs had an HR of 0.34 (95% CI 0.18-0.67). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link\">",
"     \"Statins: Possible noncardiovascular benefits\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association of statins use with a decreased risk of HCC was also demonstrated in a meta-analysis that included 10 studies with 1.6 million patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/130\">",
"     130",
"    </a>",
"    ]. Compared with patients who did not use statins, patients who took statins had a 37 percent decrease in their odds of developing HCC (odds ratio 0.63; 95% CI 0.52-0.76).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170509192\">",
"    <span class=\"h2\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based study suggested that consumption of white meat may be associated with a reduced risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/127\">",
"     127",
"    </a>",
"    ]. In addition, the consumption of fish and omega-3 fatty acids has been associated with a reduced risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/131\">",
"     131",
"    </a>",
"    ]. Higher dietary intake of vitamin E has also been associated with a decreased risk of liver cancer among patients both with and without a self-reported history of liver disease or a family history of liver cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies have implicated coffee consumption as a protective factor for liver cancer, including HCC. A meta-analysis estimated that consumption of two or more cups per day was associated with a 43 percent reduction of liver cancer (95% CI 0.49-0.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/133\">",
"     133",
"    </a>",
"    ]. The benefit was observed in individuals with and without liver disease. The authors noted that coffee contains large amounts of antioxidants, suggesting biological plausibility for the protective effect. They also noted that coffee and caffeine have been linked to lower aminotransferase levels and a reduced risk of cirrhosis, potentially further contributing to biological plausibility. Similar conclusions were reached in a second meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146269848\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of hepatocellular carcinoma (HCC) varies widely according to geographic location (",
"      <a class=\"graphic graphic_table graphicRef50081 \" href=\"UTD.htm?11/10/11438\">",
"       table 1",
"      </a>",
"      ). The distribution of HCC also differs among racial and ethnic groups within the same country, and between regions within the same country. These extreme differences in distribution of HCC are probably due to regional variations in exposure to hepatitis viruses and environmental pathogens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High-incidence regions (more than 15 cases per 100,000 population per year) include sub-Saharan Africa, the People's Republic of China, Hong Kong, and Taiwan.",
"     </li>",
"     <li>",
"      Intermediate-incidence areas include several countries in Eastern and Western Europe, Thailand, Indonesia, Jamaica, Haiti, New Zealand (Maoris), and Alaska (Eskimos).",
"     </li>",
"     <li>",
"      Low incidence areas include North and South America, most of Europe, Australia and parts of the Middle East, with fewer than three cases reported per 100,000 population per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all parts of the world, men are more likely than women to develop HCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"       5",
"      </a>",
"      ]. The disparity is more pronounced in high-incidence regions, where men are affected 2.1 to 5.7 times more frequently than women (mean 3.7:1). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sex and age distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of important risk factors for the development of HCC have been identified. Among the most important are hepatitis B carrier state, chronic hepatitis C virus infection, hereditary hemochromatosis, and cirrhosis of almost any cause. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Hepatitis B'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Chronic hepatitis and cirrhosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations of hereditary hemochromatosis\", section on 'Hepatocellular carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other factors that have been associated with an increased or decreased risk of HCC include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Environmental toxins and dietary factors (see",
"      <a class=\"local\" href=\"#H146270166\">",
"       'Environmental toxins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20494509\">",
"       'Dietary factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H170509192\">",
"       'Dietary factors'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Tobacco and alcohol abuse (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Tobacco and alcohol abuse'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Diabetes mellitus (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Diabetes mellitus'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Nonalcoholic fatty liver disease (see",
"      <a class=\"local\" href=\"#H9507724\">",
"       'Nonalcoholic fatty liver disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Alpha-1 antitrypsin deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"       \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Statins (protective) (see",
"      <a class=\"local\" href=\"#H170508993\">",
"       'Statin use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link\">",
"       \"Statins: Possible noncardiovascular benefits\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance for HCC is indicated for many patients with disorders that put them at increased risk (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643912#H61643912\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Patients who require surveillance'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Munoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In: In: Neoplasms of the Liver, Okuda K, Ishak KG (Eds), Springer, Tokyo 1989. p.3.",
"    </li>",
"    <li>",
"     Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents. Vol. 5 (IARC publications, No. 88), International Agency for Research on Cancer, Lyon, 1987.",
"    </li>",
"    <li>",
"     Bosch FX, Munoz N. Hepatocellular carcinoma in the world: Epidemiologic questions. In: Etiology, Pathology and Treatment of Hepatocellular Carcinoma in America. Advances in Applied Technology Series, Tabor E, DiBisceglie AM, Purcell RH (Eds), Gulf, Houston 1991. p.35.",
"    </li>",
"    <li>",
"     Okuda K. Epidemiology of primary liver cancer. In: Primary Liver Cancer in Japan, Tobe T (Ed), Springer-Verlag, Tokyo 1992. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/5\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/6\">",
"      Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/7\">",
"      Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529.",
"     </a>",
"    </li>",
"    <li>",
"     Cancer Incidence in five continents: IARC scientific publications volume VIII (No. 155), Parkin DM (ed), Lyon: IARCPress 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/9\">",
"      Skolnick AA. Armed with epidemiologic research, China launches programs to prevent liver cancer. JAMA 1996; 276:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/10\">",
"      Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/11\">",
"      El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/12\">",
"      Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/13\">",
"      El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/14\">",
"      Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/15\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010; 59:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/17\">",
"      Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/18\">",
"      Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/19\">",
"      Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/20\">",
"      Prates MD, Torres FO. A cancer survey in Louren&ccedil;o Marques, Portuguese East Africa. J Natl Cancer Inst 1965; 35:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/21\">",
"      Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med 2008; 121:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/22\">",
"      Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011; 9:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/23\">",
"      Bralet MP, R&eacute;gimbeau JM, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000; 32:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/24\">",
"      Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994; 17:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/25\">",
"      Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/26\">",
"      Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/27\">",
"      Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/28\">",
"      Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/29\">",
"      Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/30\">",
"      Chen CJ, Yang HI, Iloeje U, et al. Models to predict hepatocellular carcinoma in patients with chronic hepatitis B infection: The REVEAL HBV study (abstract). Hepatology 2005; 42 Suppl 1:714A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/31\">",
"      Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/32\">",
"      Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/33\">",
"      Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/34\">",
"      Lu SN, Lin TM, Chen CJ, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/35\">",
"      Chen CJ, Liang KY, Chang AS, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/36\">",
"      Lin TM, Chen CJ, Lu SN, et al. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res 1991; 11:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/37\">",
"      Yu MW, You SL, Chang AS, et al. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51:5621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/38\">",
"      Tsai JF, Jeng JE, Ho MS, et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/39\">",
"      Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/40\">",
"      Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/41\">",
"      Chen CJ, Yang HI, Iloeje UH, et al. Time-dependent relative risk of hepatocellular carcinoma for markers of chronic hepatitis B. The REVEAL HBV study (abstract). Hepatology 2005; 42 Suppl 1:722A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/42\">",
"      Tong MJ, Blatt LM, Kao JH, et al. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007; 27:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/43\">",
"      Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/44\">",
"      Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/45\">",
"      Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/46\">",
"      Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/47\">",
"      Shen YC, Hsu C, Cheng CC, et al. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 2012; 82:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/48\">",
"      Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011; 29:3643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/49\">",
"      Huang YT, Yang HI, Jen CL, et al. Suppression of hepatitis B virus replication by hepatitis C virus: combined effects on risk of hepatocellular carcinoma (abstract). Hepatology 2005; 42 (Suppl 1):230A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/50\">",
"      Benvegn&ugrave; L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/51\">",
"      Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/52\">",
"      Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/53\">",
"      Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/54\">",
"      Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/55\">",
"      J Hepatol 2013; 58:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/56\">",
"      Li Q, Yu CH, Yu JH, et al. ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS One 2012; 7:e29928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/57\">",
"      B&oslash;rresen ML, Koch A, Biggar RJ, et al. Hepatocellular carcinoma and other liver disease among Greenlanders chronically infected with hepatitis B virus: a population-based study. J Natl Cancer Inst 2011; 103:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/58\">",
"      Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/59\">",
"      Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/60\">",
"      Omland LH, Jepsen P, Krarup H, et al. Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study. Int J Cancer 2012; 130:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/61\">",
"      Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/62\">",
"      Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/63\">",
"      Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/64\">",
"      Kamegaya Y, Hiasa Y, Zukerberg L, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 2005; 41:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/65\">",
"      Maki A, Kono H, Gupta M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007; 14:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/66\">",
"      Suruki RY, Mueller N, Hayashi K, et al. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev 2006; 15:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/67\">",
"      Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/68\">",
"      Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009; 50:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/69\">",
"      Stankovic-Djordjevic D, Djordjevic N, Tasic G, et al. Hepatitis C virus genotypes and the development of hepatocellular carcinoma. J Dig Dis 2007; 8:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/70\">",
"      Bruno S, Crosignani A, Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/71\">",
"      Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/72\">",
"      Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/73\">",
"      Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011; 54:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/74\">",
"      Morgan RL, Baack B, Smith BD, et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies. Ann Intern Med 2013; 158:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/75\">",
"      George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/76\">",
"      Zaman SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer 1990; 65:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/77\">",
"      Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990; 211:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/78\">",
"      Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/79\">",
"      Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/80\">",
"      Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/81\">",
"      Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/82\">",
"      Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/83\">",
"      Bosch FX, Ribes J, Borr&agrave;s J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/84\">",
"      Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/85\">",
"      Unsal H, Yakicier C, Mar&ccedil;ais C, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994; 91:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/86\">",
"      Yan RQ, Su JJ, Huang DR, et al. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J Cancer Res Clin Oncol 1996; 122:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/87\">",
"      Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998; 27:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/88\">",
"      Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/89\">",
"      Ueno Y, Nagata S, Tsutsumi T, et al. Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis 1996; 17:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/90\">",
"      Tsai JF, Chuang LY, Jeng JE, et al. Betel quid chewing as a risk factor for hepatocellular carcinoma: a case-control study. Br J Cancer 2001; 84:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/91\">",
"      Tsai JF, Jeng JE, Chuang LY, et al. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study. Medicine (Baltimore) 2003; 82:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/92\">",
"      Tsai JF, Jeng JE, Chuang LY, et al. Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis. Medicine (Baltimore) 2004; 83:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/93\">",
"      Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/94\">",
"      Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/95\">",
"      Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/96\">",
"      Mayans MV, Calvet X, Bruix J, et al. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer 1990; 46:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/97\">",
"      Tanaka K, Hirohata T, Takeshita S, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992; 51:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/98\">",
"      Mohamed AE, Kew MC, Groeneveld HT. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/99\">",
"      Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/100\">",
"      Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology 1994; 106:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/101\">",
"      Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/102\">",
"      Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/103\">",
"      Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008; 6:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/104\">",
"      Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 2010; 31:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/105\">",
"      Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 2013; 177:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/106\">",
"      Brechot C, Nalpas B, Feitelson MA. Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med 1996; 16:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/107\">",
"      Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26:39S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/108\">",
"      El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/109\">",
"      Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/110\">",
"      Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/111\">",
"      Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/112\">",
"      Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol 2012; 56:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/113\">",
"      Li Q, Li WW, Yang X, et al. Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Int J Cancer 2012; 131:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/114\">",
"      Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/115\">",
"      Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/116\">",
"      Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/117\">",
"      Yang WS, Va P, Bray F, et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One 2011; 6:e27326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/118\">",
"      Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/119\">",
"      Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/120\">",
"      Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/121\">",
"      Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 Suppl 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/122\">",
"      Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/123\">",
"      Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/124\">",
"      Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/125\">",
"      Abu Dayyeh BK, Yang M, Fuchs BC, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/126\">",
"      Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/127\">",
"      Freedman ND, Cross AJ, McGlynn KA, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst 2010; 102:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/128\">",
"      Cross AJ, Leitzmann MF, Gail MH, et al. A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med 2007; 4:e325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/129\">",
"      Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/130\">",
"      Singh S, Singh PP, Singh AG, et al. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. Gastroenterology 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/131\">",
"      Sawada N, Inoue M, Iwasaki M, et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 2012; 142:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/132\">",
"      Zhang W, Shu XO, Li H, et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst 2012; 104:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/133\">",
"      Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007; 132:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/38/25194/abstract/134\">",
"      Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007; 46:430.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3599 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25194=[""].join("\n");
var outline_f24_38_25194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H146269848\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146270472\">",
"      Geographic variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sex and age distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Racial and ethnic variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159004431\">",
"      - Viral load",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159005272\">",
"      - Active viral replication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159004439\">",
"      - Inactive carriers or resolved infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159005743\">",
"      - Effect of HBV treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159005636\">",
"      - Sex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146123953\">",
"      - Coinfection with HCV or HDV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159004447\">",
"      - Other factors associated with HCC in patients with HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic hepatitis and cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146270166\">",
"      Environmental toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146270173\">",
"      - Aflatoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146270180\">",
"      - Contaminated drinking water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146270187\">",
"      - Betel nut chewing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tobacco and alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9507724\">",
"      Nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Epidermal growth factor polymorphisms and receptor expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20494509\">",
"      Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170508916\">",
"      PROTECTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170508993\">",
"      Statin use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170509192\">",
"      Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H146269848\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3599|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/51/2871\" title=\"figure 1\">",
"      Cumulative incidence of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/10/11438\" title=\"table 1\">",
"      Incidence of HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38476\" title=\"table 2\">",
"      HCC surveillance recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/52/9035\" title=\"table 3\">",
"      HCC aflatoxin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_38_25195="Causes of hypophosphatemia";
var content_f24_38_25195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypophosphatemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Internal redistribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased insulin secretion, particularly during refeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute respiratory alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hungry bone syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased intestinal absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antacids containing aluminum or magnesium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatorrhea and chronic diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D deficiency or resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased urinary excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary and secondary hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D deficiency or resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary hypophosphatemic rickets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oncogenic osteomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fanconi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other -&nbsp;acetazolamide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25195=[""].join("\n");
var outline_f24_38_25195=null;
var title_f24_38_25196="Platelet function tests";
var content_f24_38_25196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    List of established platelet function tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Platelet function test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aspects of platelet function measured",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding Time",
"       </td>",
"       <td>",
"        In vivo screening test",
"       </td>",
"       <td>",
"        Physiological",
"       </td>",
"       <td>",
"        Insensitive, Invasive &amp; high inter-operator variability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Aggregometry -&nbsp;Turbidometric methods",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Responsiveness to Panel of Agonists",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diagnostic",
"       </td>",
"       <td>",
"        Labor intensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Physiological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggregometry -&nbsp;impedance methods",
"       </td>",
"       <td>",
"        Responsiveness to Panel of Agonists",
"       </td>",
"       <td>",
"        Whole blood test",
"       </td>",
"       <td>",
"        Insensitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggregometry and luminescence",
"       </td>",
"       <td>",
"        Combined aggregation and ADP release",
"       </td>",
"       <td>",
"        More information",
"       </td>",
"       <td>",
"        Semi-quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenine Nucleotides",
"       </td>",
"       <td>",
"        Stored and Released ADP",
"       </td>",
"       <td>",
"        Sensitive",
"       </td>",
"       <td>",
"        Specialized equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Thromboelastography (TEG)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Global Haemostasis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Predicts bleeding",
"       </td>",
"       <td>",
"        Measures Clot properties only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insensitive to aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glass Filterometer",
"       </td>",
"       <td>",
"        High shear platelet function",
"       </td>",
"       <td>",
"        Simple",
"       </td>",
"       <td>",
"        Requires blood counter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet Release Markers eg. BetaTG PF4",
"       </td>",
"       <td>",
"        In vivo platelet activation markers",
"       </td>",
"       <td>",
"        Simple, systemic measure of platelet",
"       </td>",
"       <td>",
"        Prone to artifact",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harrison, P. Progress in the Assessment of Platelet Function. Br J Haematol 2000; 111:733. Copyright &copy; 2000 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25196=[""].join("\n");
var outline_f24_38_25196=null;
var title_f24_38_25197="Grading scale for aging skin";
var content_f24_38_25197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comprehensive grading scale of rhytides, laxity, and photodamage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Grading scale",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Descriptive parameter",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Categories of skin aging and photodamage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Rhytides",
"       </td>",
"       <td class=\"subtitle2\">",
"        Laxity",
"       </td>",
"       <td class=\"subtitle2\">",
"        Elastosis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dyschromia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Erythema telangiectasia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Keratoses",
"       </td>",
"       <td class=\"subtitle2\">",
"        Texture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Wrinkles in motion, few, superficial",
"       </td>",
"       <td>",
"        Localized to NL folds",
"       </td>",
"       <td>",
"        Early, minimal yellow hue",
"       </td>",
"       <td>",
"        Few (1-3) discrete small (&lt;5 mm) lentigines",
"       </td>",
"       <td>",
"        Pink E or few T, localized to single site",
"       </td>",
"       <td>",
"        Few",
"       </td>",
"       <td>",
"        Subtle irregularity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Wrinkles in motion, multiple, superficial",
"       </td>",
"       <td>",
"        Localized, NL and early ML folds",
"       </td>",
"       <td>",
"        Yellow hue or early, localized PO EB",
"       </td>",
"       <td>",
"        Several (3-6), discrete small lentigines",
"       </td>",
"       <td>",
"        Pink E or several T localized to 2 sites",
"       </td>",
"       <td>",
"        Several",
"       </td>",
"       <td>",
"        Mild irregularity in few areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Wrinkles at rest, few, localized, superficial",
"       </td>",
"       <td>",
"        Localized, NL/ML folds, early jowels, early submental/SM",
"       </td>",
"       <td>",
"        Yellow hue, localized PO EB",
"       </td>",
"       <td>",
"        Multiple (7-10), small lentigines",
"       </td>",
"       <td>",
"        Red E or multiple T localized to 2 sites",
"       </td>",
"       <td>",
"        Multiple, small",
"       </td>",
"       <td>",
"        Rough in few, localized sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Wrinkles at rest, multiple, localized, superficial",
"       </td>",
"       <td>",
"        Localized, prominent NL/ML folds, jowels and SM",
"       </td>",
"       <td>",
"        Yellow hue, PO and malar EB",
"       </td>",
"       <td>",
"        Multiple, small and few large lentigines",
"       </td>",
"       <td>",
"        Red E or multiple T, localized to 3 sites",
"       </td>",
"       <td>",
"        Multiple, large",
"       </td>",
"       <td>",
"        Rough in several localized areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Advanced",
"       </td>",
"       <td>",
"        Wrinkles at rest, multiple, forehead, PO and perioral sites, superficial",
"       </td>",
"       <td>",
"        Prominent NL/ML folds, jowels and SM, early neck strands",
"       </td>",
"       <td>",
"        Yellow hue, EB involving PO, malar, and other sites",
"       </td>",
"       <td>",
"        Many (10-20) small and large lentigines",
"       </td>",
"       <td>",
"        Violaceous E or many T, multiple sites",
"       </td>",
"       <td>",
"        Many",
"       </td>",
"       <td>",
"        Rough in multiple, localized sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        Advanced",
"       </td>",
"       <td>",
"        Wrinkles at rest, multiple, generalized, superficial; few, deep",
"       </td>",
"       <td>",
"        Deep NL/ML folds, prominent jowels and SM, prominent neck strands",
"       </td>",
"       <td>",
"        Deep yellow hue, extensive EB with little uninvolved skin",
"       </td>",
"       <td>",
"        Numerous (&gt;20) or multiple large with little uninvolved skin",
"       </td>",
"       <td>",
"        Violaceous E, numerous T, little uninvolved skin",
"       </td>",
"       <td>",
"        Little uninvolved skin",
"       </td>",
"       <td>",
"        Mostly rough, little uninvolved skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Wrinkles throughout, numerous, extensively distributed, deep",
"       </td>",
"       <td>",
"        Marked NL/ML folds, jowels and SM, neck redundancy and strands",
"       </td>",
"       <td>",
"        Deep yellow hue, EB throughout, comedones",
"       </td>",
"       <td>",
"        Numerous, extensive, no uninvolved skin",
"       </td>",
"       <td>",
"        Deep, violaceous E, numerous T throughout",
"       </td>",
"       <td>",
"        No uninvolved skin",
"       </td>",
"       <td>",
"        Rough throughout",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     E: Erythema; EB: elastotic beads; ML: melolabial; NL: nasolabial; PO: periorbital; SM: submental/submandibular; T: telangiectasia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: Nonablative fractional, and ablative laser resurfacing. J Am Acad Dermatol 2008; 58:719. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25197=[""].join("\n");
var outline_f24_38_25197=null;
var title_f24_38_25198="Effect of renal function on growth in children with CKD";
var content_f24_38_25198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The effect of baseline renal function on growth from the NAPRTCS registry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 490px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) demonstrate the impact of renal function on growth in children with chronic renal insufficiency.",
"    <div class=\"footnotes\">",
"     Height Z score: the number of standard deviations from the mean height for age; GFR: glomerular filtration rate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2008 Annual Report. Renal transplantation, dialysis, and chronic renal insufficiency. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25198=[""].join("\n");
var outline_f24_38_25198=null;
var title_f24_38_25199="DISH radiograph ankle";
var content_f24_38_25199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Affected ankle in diffuse idiopathic skeletal hyperostosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of ankle and hindfoot in a patient with diffuse idiopathic skeletal hyperostosis (DISH) reveals a small plantar osteophyte (large arrow) as well as a larger dorsal calcaneal spur (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Esdaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_38_25199=[""].join("\n");
var outline_f24_38_25199=null;
              